WO2010021693A2 - Mif modulators - Google Patents

Mif modulators Download PDF

Info

Publication number
WO2010021693A2
WO2010021693A2 PCT/US2009/004704 US2009004704W WO2010021693A2 WO 2010021693 A2 WO2010021693 A2 WO 2010021693A2 US 2009004704 W US2009004704 W US 2009004704W WO 2010021693 A2 WO2010021693 A2 WO 2010021693A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
group
compound according
alkyl
mif
Prior art date
Application number
PCT/US2009/004704
Other languages
French (fr)
Other versions
WO2010021693A3 (en
Inventor
William Jorgensen
Richard J. Bucala
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41707595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010021693(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP09808499A priority Critical patent/EP2326631A4/en
Priority to US13/059,762 priority patent/US20120040974A1/en
Priority to BRPI0917394A priority patent/BRPI0917394A2/en
Priority to EA201170349A priority patent/EA201170349A1/en
Priority to MX2011001872A priority patent/MX2011001872A/en
Priority to AU2009283195A priority patent/AU2009283195A1/en
Priority to JP2011523805A priority patent/JP2012500260A/en
Application filed by Yale University filed Critical Yale University
Priority to CN200980141108XA priority patent/CN102186833A/en
Priority to CA2733554A priority patent/CA2733554A1/en
Publication of WO2010021693A2 publication Critical patent/WO2010021693A2/en
Priority to US12/773,430 priority patent/US9643922B2/en
Publication of WO2010021693A3 publication Critical patent/WO2010021693A3/en
Priority to IL211170A priority patent/IL211170A0/en
Priority to US13/100,922 priority patent/US9540322B2/en
Priority to US15/656,555 priority patent/US10202343B2/en
Priority to US16/229,069 priority patent/US11584717B2/en
Priority to US16/999,015 priority patent/US20200377457A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to novel heterocyclic compounds, pharmaceutical compositions and their use in modulating levels of MIF expression and in treating disorders associated with high or low levels of MIF expression.
  • Macrophage migration inhibitory factor is a pro-inflammatory cytokine that is released by T-cells and macrophages. It is viewed to play a key role in a wide range of diseases including rheumatoid arthritis, sepsis, atherosclerosis, asthma, and acute respiratory distress syndrome. MIF also is involved in cell proliferation and differentiation, and anti-MIF antibodies suppress tumor growth and angiogenesis. The biology of MIF and potential biomedical significance of MIF-inhibition are striking, as reviewed elsewhere. Orita, et al., (2002), Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors, Curr. Pharm. Res. 8, 1297-1317 ("Orita 2002"); Lolis, et al.
  • MIF macrophage migration inhibitory factor
  • a glucocorticoid-induced regulator of cytokine production reveals a unique architecture.
  • the 114-residue MIF monomer has a ⁇ / ⁇ / ⁇ motif and three monomers associate to form a symmetrical trimer.
  • the trimer is toroidal with a solvent-filled central channel.
  • MIF was also found to show structural homology to two prokaryotic tautomerases, and phenylpyruvate and D-dopachrome were discovered to be MIF tautomerase substrates.
  • L-dopachromes are substrates for a response mechanism of invertebrates to microbial invasion, the catalytic activity of mammalian MIF is likely vestigial.
  • Site-directed mutagenesis and crystallography have identified the MIF active site, and mechanisms for the tautomerase activity have been proposed with key roles for Prol as a base and Lys32 as a proton donor (Lubetsky, J. et al. (1999), Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity.
  • MIF trimer has three tautomerase active sites, which are well defined cavities located at the interfaces of the monomer subunits.
  • CD74 macrophage migration inhibitory factor
  • the tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277, 24976-24982).
  • a key feature in the X- ray structures is a hydrogen bond between the phenolic OH and the side-chain CO of Asn97, which forms a backstop for the active site channel. Further optimization enhanced the potency from 7 ⁇ M for ( ⁇ -ISO-1 to 550 nM for (R)-Il (Cheng, K. F. & Al- Abed, Y. (2006) Critical modifications of the ISO-I scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg. Med. Chem. Lett. 16, 3376- 3379).
  • MIF macrophage migration inhibitory factor
  • PCT WO2006045505 discloses MIF inhibitors.
  • the MIF inhibitors of PCT WO2006045505 are 3,4-dihydro-benzo[e][l,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C3-8)cycloalkyl, (Cl-4)alkyl(C3-8)cycloalkyl, (C6-18)aryl or (C6-18)aryl(Cl-4)alkyl.
  • PCT WO2007070961 discloses MIF-inhibiting benzimidazolone analogues and derivatives.
  • Various objects of the invention relate to chemical compounds which modulate Macrophage migration inhibitory factor (MIF).
  • MIF Macrophage migration inhibitory factor
  • Additional objects of the invention relate to pharmaceutical compounds, methods of modulating MIF and/or treating disease states and/or conditions where MIF modulation (especially agonist and antagonist activity is relevant).
  • the present inventors have pursued the development of novel inhibitors and agonists for the interaction of MIF with its receptor, CD74.
  • the work combines computer-aided compound design, synthetic organic chemistry, and biological assaying. Lead generation proceeded by both de novo design and molecular docking of large libraries of commercially available compounds. See Jorgensen, W. L. (2004), The Many Roles of Computation in Drug Discovery. Science 303, 1813-1818, and Jorgensen W. L., Accounts of Chemical Research, Vol. 42, No. 6, pp. 724-733 (June, 2009), relevant portions of which are incorporated by reference herein.
  • the present invention is directed to bicyclic compounds according to the chemical structure (I):
  • X is O, S, N-RTM 1 or CR XC1 R XC2 ; Y is N-R ⁇ ' or CR ⁇ R ⁇ and
  • Z is O, S, N-R 2 * 1 or CR ZC1 R ZC2 , with the proviso that at least one of X or Z is N-RTM 1 and X and Z are other than O, when Y is O;
  • RTM 1 is absent, H, an optionally substituted C 1 -C 8 alkyl, alkene or alkyne group, an optionally substituted Ci-C 8 acyl group, an optionally substituted (CH 2 )J -phenyl group or an optionally substituted (CH 2 )m-heterocyclic (preferably heteroaryl) group;
  • R 2 * 1 is absent, H, an optionally substituted Ci-C 8 alkyl, alkene or alkyne group, an optionally substituted C]-C 8 acyl group, an optionally substituted (CH 2 )j-phenyl group or an optionally substituted (CH 2 )m-heterocyclic (preferably heteroaryl) group;
  • R XC2 is H, halogen, cyano, an optionally substituted C 1 -Cg alkyl, alkene or alkyne group
  • R is an optionally substituted C 1 -C 3 group when R is an optionally substituted Ci -C 3 group
  • an optionally substituted Ci-C 8 acyl group preferably R is an optionally substituted
  • R YC2 is H, halogen, cyano, an optionally substituted Ci-C 8 alkyl, alkene or alkyne group
  • R is an optionally substituted Ci-C 3 group when R is an optionally substituted Cj-C 3 group
  • an optionally substituted CpC 7 acyl group preferably R is an optionally substituted
  • R ZC2 is H, halogen, cyano, an optionally substituted C 1 -C 8 alkyl, alkene or alkyne group
  • R is an optionally substituted Ci -C 3 group when R is an optionally substituted Ci-C 3 group
  • an optionally substituted Cj-Cs acyl group preferably R is an optionally substituted
  • Ce alkyl group an optionally substituted (CH 2 )J -phenyl group or an optionally substituted
  • R A and R B together form an optionally substituted 5, 6 or 7 membered carbocyclic or heterocyclic ring (preferably an optionally substituted 6-membered aromatic or heteroaromatic ring, more preferably an optionally substituted phenyl ring or a heteroaromatic ring containing one nitrogen group, preferably a pyridyl group); each j is independently 0, 1, 2, 3, 4 or 5; and each m is 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
  • the present invention is directed to 6:5 fused ring compounds according to the structure (II):
  • Ri and R 2 are each independently H, OH, COOH, halogen (F, Cl, Br, I), CN, OH, optionally substituted Ci-C 8 alkyl, optionally substituted O-(C r C 6 )alkyl, SH, S-(d-C 6 )alkyl, optionally substituted Ci-C 8 acyl, optionally substituted C 2 -C 8 ether, optionally substituted C 2 -C 8 ester or carboxyester, optionally substituted C 2 -C 8 thioester, amide optionally subsituted with a C 1 - C 6 alkyl group, carboxyamide optionally substituted with one or two Ci-C 6 alkyl or alkanol groups, and amine optionally substituted with one or two C 1 -C 6 alkyl or alkanol groups.
  • R, and R 2 are independently H, CH 3 , CH 2 CH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 , OH, 0CH3, SH, SCH 3 , F, Cl, Br or I.
  • compounds according to the present invention have the following chemical structures A-N as depicted below
  • RTM 1 , R w ⁇ , R YC2 and R ZC2 are as described above for compound (II);
  • R 1 , R 2 , Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each independently H, hydroxyl, optionally substituted CpCg alkyl, alkene or alkyne group, optionally substituted Ci-C 8 acyl group, optionally substituted
  • (CH 2 ) j -carbocyclic group wherein said carbocyclic group forms an optionally substituted 5, 6 or 7-membered ring (preferably, a (CH 2 ) j -phenyl group, where the phenyl group is optionally substituted), or an optionally substituted (CH 2 ) m -heterocyclic group (preferably, an optionally substituted heteroaryl) group, alkoxy, halogen, carboxylic acid, cyano, ether, ester, acyl, nitro, amine (including mono- or di- alkyl substituted amines), or (CH 2 )j-OH;
  • R 3 is H, an optionally substituted Cj-C 6 alkyl group, an optionally substituted O-(Ci-C 6 )alkyl, an optionally substituted aryl group or heterocyclic group; each j is independently 0, 1, 2, 3, 4 or 5; and each m is 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
  • R] and R 2 are H, CH 3 , CH 2 CH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 ,
  • R 3 is preferably an optionally substituted phenyl group or an optionally substituted heterocyclic group, preferably an optionally substituted heteroaryl group containing a single ring or fused rings (preferably 6:5) such as benzofuran, indole or 2,3-dihydroindole.
  • compound (A) represents benooxazolone derivatives, including N-benzyl analogs (B).
  • C) and (D) represent benzoimidazole and benzofuran derivatives, including acyl analogs (E) and (F) where R 3 can be a small group or another mono or bicyclic heterocycle such as a benzofuran, indole or 2,3-dihydroindole.
  • R 3 can be a small group or another mono or bicyclic heterocycle such as a benzofuran, indole or 2,3-dihydroindole.
  • Additional representative structures are substituted indoles G, benzopyrazoles H, benzotriazoles J, benzooxazoles K, benzoisoxazoles L, benzothiazolones M, and benzoisothiazolones N, and corresponding compounds with oxygen replacing sulfur or vice versa.
  • R 1 and R 2 are each independently H, CH 3 , CH 2 CH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 , OH, OCH3, SH, SCH 3 , F, Cl, Br or I.
  • Rj and R 2 are each independently selected from the group consisting of H, hydroxyl, optionally substituted Ci-C 8 alkyl, or (CH 2 )J-OH; and at least one OfZi-Z 5 is a Cj-C 6 alkoxy group.
  • compounds of the invention provide benzooxazolone derivatives, A, including the iV-benzyl analogs B.
  • R 1 , R 2 and Zi - Z 5 are each independently small aliphatic or heteroatom containing groups; primary examples are H, CH 3 , CH 2 CH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 , OH, OCH 3 , SH, SCH 3 , F, Cl, Br, and I.
  • compounds according to the present invention have the following chemical structure (III):
  • R A1 and R B1 form a 5, 6 or 7 membered optionally substituted carbocyclic (preferably a phenyl) ring or heterocyclic (preferably, heteroaryl, including a pyridyl) group;
  • R 6 is H, an optionally substituted Ci-C 8 alkyl, alkene or alkyne group, an optionally substituted C 5 -C H (CH 2 ) j -carbocyclic group wherein said carbocyclic group preferably forms an optionally substituted 5, 6 or 7-membered ring (preferably, a (CH 2 ) j -aryl group, e.g., a
  • each j is independently 0, 1, 2, 3, 4 or 5; and each m is indepdendently 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
  • R 6 is an optionally substituted C 5 -Cn (CH 2 ) j -carbocyclic group wherein said carbocyclic group forms a 5, 6 or 7-membered ring (preferably, an optionally substituted (CH 2 )j-phenyl group), or an optionally substituted (CH 2 ) m -heterocyclic group (preferably, an optionally substituted (CH 2 ) m -heteroaryl) group; and (2) R ⁇ I and R B1 form an optionally substituted phenyl or pyridyl group.
  • R 6 is an optionally substituted (CH 2 ) j -phenyl group, or an optionally substituted (CH 2 ) m - heterocyclic group (preferably, an optionally substituted (CH 2 ) m -heteroaryl) group; and (2) one of R A1 and R B1 is H and the other is an optionally substituted (CH 2 ) j -phenyl group.
  • R 6 is (a) (CH 2 ) j -phenyl group, which is optionally substituted with no more than three substituents selected from halogen (especially fluoro and chloro), CH 3 , CH 2 CH 3 , CF 3 , CH 2 OH, CH 2 OCH 3 , OCH 3 , and CN, or is (b) a (CH 2 ) m -heteroaryl group, which is optionally substituted with no more than three substituents selected from halogen (especially fluoro and chloro), CH 3 , CH 2 CH 3 , CF 3 , CH 2 OH, CH 2 OCH 3 , OCH 3 , and CN ; (2) R A1 and R B1 form a phenyl group which is optionally substituted with no more than three substituents selected from halogen (especially fluoro and chloro), CH 3 , CH 2 CH 3 , CF 3 , CH 2 OH, CH 2 OCH 3 , and CN ; (2) R A1 and R
  • the present invention is directed to a compound according to the chemical structure B:
  • R 1 and R 2 are each independently selected from H, OH, CN, NO 2 , halogen (F, Cl, Br, I, preferably Br, Cl or F), Ci-C 4 alkyl which is optionally substituted with at least one hydroxyl (from 1 to 3 hydroxyls ) or at least one and preferably .at least three halogens, preferably F, or a - ⁇ CH 2 ) j 0R a , -(CH 2 ) j C(O)R a or -(CH 2 ) j 0C(0)R a group, where R a is H, a C1-C 3 alkyl group which is optionally substituted with at least one hydroxyl group (1 to 3) or at least one halogen, preferably at least three halogen groups, preferably F and j is O, 1, 2 or 3; Z 1 , Z 2 , Z 3 , Z 4 and Zs are each independently H, C 1 -C 3 alkyl group which is optionally substituted
  • Z 4 and Z 5 are both H.
  • Ri is H, CH 3 , OCH 3 , F or OH;
  • R 2 is H 5 CH 3 or OH;
  • Z is H or OCH 3 ;
  • Z 2 is H, OH or OCH 3 ;
  • Z 3 is H or OCH 3 ;
  • Z 4 is H and Z 5 is H.
  • Preferred compounds include a compound where Ri is CH 3 , R 2 is H, Zi is OCH 3 , Z 2 is H, Z 3 is H, Z 4 is H and Z 5 is H; a compound where Ri is CH 3 , R 2 is H, Zi is H, Z 2 is H, Z 3 is H, Z 4 is H and Z 5 is H; a compound where Ri is H, R 2 is OH, Zi is H, Z 2 is H, Z 3 is OCH 3 , Z 4 is H and Z 5 is H; a compound where Rj is F, R 2 is H, Zi is H, Z 2 is H, Z 3 is H, Z 4 is H and Z 5 is H; a compound where Ri is CH 3 , R 2 is H, Zi is H, Z 2 is OH, Z 3 is H, Z 4 is H and Z 5 is H; and a compound where Ri is OH, R 2 is H, Zi is OCH 3 , Z 2 is OCH 3 , Z 3 is H, Z 4 is H and Z 5 is H; and a compound where
  • Ri and R 2 are each independently selected from H, OH, CN, NO 2 , halogen (F, Cl, Br, I, preferably Br, Cl or F), Ci-C 4 alkyl which is optionally substituted with at least one hydroxyl (from 1 to 3 hydroxyls ) or at least one and preferably at least three halogens, preferably F, or a -(CH 2 ) j 0R a , -(CH 2 ) j C(O)R a or -(CH 2 ) j OC(O)R a group, where R a is H, a Ci -C 3 alkyl group which is optionally substituted with at least one hydroxyl group (1 to 3) or at least one halogen, preferably at least three halogen groups, preferably F; and j is O, 1, 2 or 3;
  • Zi, Z 2 , Z 3 , Z 4 and Z 5 are each independently H, Ci-C 3 alkyl group which is optionally substituted with at least one hydroxyl group (from 1 to 3) or at least one halogen, preferably at least three halogen groups, preferably F, or a -(CH 2 ) j OR a , -(CH 2 ) j C(O)R a or -(CH 2 ) j OC(O)R 3 group, where R a is H, a Cj-C 3 alkyl group which is optionally substituted with at least one hydroxyl group (1 to 3) or at least one halogen, preferably at least three halogen groups, preferably F; and j is 0, 1, 2 or 3, or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
  • Preferred compounds include a compound where R 1 is H, R 2 is F, Z 1 is H, Z 2 is H, Z 3 is Cl, Z 4 is H and Z 5 is H; a compound where Ri is F, R 2 is H, Zi is H, Z 2 is H, Z 3 is Cl, Z 4 is H and Z 5 is H; a compound where Ri is F, R 2 is H, Zi is H, Z 2 is CH 2 OAc, Z 3 is H, Z 4 is H and Z 5 is H; and a compound where Rj is CN, R 2 is H, Zi is H, Z 2 is H, Z 3 is Cl, Z 4 is H and Z 5 is H.
  • compositions comprise an effective amount of one or more compounds as described above, optionally in combination with a pharmaceutically acceptable carrier, excipient or additive.
  • Pharmaceutical compositions may also include, in addition to the present compounds, at least one additional compound, including another agent which modulates MIF.
  • the present application is directed to the modulation (enhancement or inhibition) of the action of MIF in a patient wherein said method comprises administering an effective amount of a compound according to the present invention in combination with a pharmaceutically acceptable carrier, additive or excipient.
  • the present application is directed to the treatment of a "disease associated with high MIF expression" or a "disease associated with low MIF expression", as defined hereinafter, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising any one or more of the compounds previously described above, optionally in combination (coadministered) with another active agent, preferably another agent which modulates levels of MIF expression as otherwise disclosed herein.
  • compositions comprising the aforementioned novel compounds are also provided by the invention.
  • compound refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, optical isomers thereof, as well as pharmaceutically acceptable salts thereof.
  • compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and/or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds.
  • a bond between atoms is a single bond or double bond according to the context of the bond's use in the compound, which depends on the atoms (and substituents) used in defining the present compounds.
  • a carbon (or other) atom is used and the context of the use of the atom calls for a double bond or single bond to link that atom with an adjacent atom in order to maintain the appropriate valence of the atoms used, then that bond is considered a double bond or a single bond.
  • patient or “subject” is used throughout the specification within context to describe an animal, generally a mammal and preferably a human, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided.
  • treatment including prophylactic treatment
  • patient refers to that specific animal.
  • Hydrocarbon refers to any monovalent (or divalent in the case of alkylene groups) radical containing carbon and hydrogen, which may be straight, branch- chained or cyclic in nature.
  • Hydrocarbons include linear, branched and cyclic hydrocarbons, including alkyl groups, alkylene groups, saturated and unsaturated hydrocarbon groups, including aromatic groups both substituted and unsubstituted, alkene groups (containing double bonds between two carbon atoms) and alkyne groups (containing triple bonds between two carbon atoms). In certain instances, the terms substituted alkyl and alkylene are sometimes synonymous.
  • Alkyl refers to a fully saturated monovalent radical containing carbon and hydrogen, and which may be cyclic, branched or a straight chain.
  • alkyl groups are methyl, ethyl, n-butyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, isopropyl, 2-methyl- propyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylethyl, cyclohexylethyl and cyclohexyl.
  • Preferred alkyl groups are C 1 -C 6 alkyl groups.
  • Alkylene refers to a fully saturated hydrocarbon which is divalent (may be linear, branched or cyclic) and which is optionally substituted. Preferred alkylene groups are C 1 -C 6 alkylene groups. Other terms used to indicate substitutuent groups in compounds according to the present invention are as conventionally used in the art.
  • Aryl or “aromatic”, in context, refers to a substituted or unsubstituted monovalent aromatic radical having a single ring (e.g. , benzene or phpenyl) or multiple condensed rings (e.g., naphthyl, anthracenyl, phenanthryl) and can be can be bound to the compound according to the present invention at any position on the ring(s) or as otherwise indicated in the chemical structure presented.
  • aryl groups in context, may include heterocyclic aromatic ring systems "heteroaryl” groups having one or more nitrogen, oxygen, or sulfur atoms in the ring (moncyclic) such as imidazole, furyl, pyrrole, furanyl, thiene, thiazole, pyridine, pyrimidine, pyrazine, triazole, oxazole, indole or fused ring systems (bicyclic, tricyclic), among others, which may be substituted or unsubstituted as otherwise described herein.
  • heteroaryl having one or more nitrogen, oxygen, or sulfur atoms in the ring (moncyclic) such as imidazole, furyl, pyrrole, furanyl, thiene, thiazole, pyridine, pyrimidine, pyrazine, triazole, oxazole, indole or fused ring systems (bicyclic, tricyclic), among others, which may be substituted or unsubstitute
  • cyclic shall refer to an optionally substituted carbocyclic or heterocyclic group, preferably a 5- or 6-membered ring or fused rings (two or three rings) preferably containing from 8 to 14 atoms.
  • a heterocyclic ring or group shall contain at least one monocyclic ring containing between 3 and 7 atoms of which up to four of those atoms are other than carbon and are selected from nitrogen, sulfur and oxygen.
  • Carbocyclic and heterocyclic rings according to the present invention may be unsaturated or saturated.
  • Preferred carbocyclic groups are unsaturated, and include phenyl groups, among other groups.
  • Preferred heterocyclic groups are heteroaryl or heteroaromatic.
  • heterocyclic group refers to an aromatic or non-aromatic cyclic group having 3 to 14 atoms, preferably 5 to 14 atoms forming the cyclic ring(s) and including at least one hetero atom such as nitrogen, sulfur or oxygen among the atoms forming the cyclic ring, which is an aromatic heterocyclic group (also, “heteroaryl” or “heteroaromatic”) in the former case and a “non-aromatic heterocyclic group” in the latter case.
  • aromatic heterocyclic group also, “heteroaryl” or “heteroaromatic
  • heterocyclic group therefore include specific examples of the aromatic heterocyclic group and specific examples of the non- aromatic heterocyclic group, both of which groups fall under the rubric "heterocyclic group" as otherwise described herein.
  • heterocyclic groups which may be mentioned for use in the present invention within context include nitrogen-containing aromatic heterocycles such as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine, pyrazole, imidazole, triazole, tetrazole, indole, isoindole, indolizine, purine, indazole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazo
  • the "5- to 14-membered aromatic heterocyclic group” there may be mentioned preferably, pyridine, triazine, pyridone, pyrimidine, imidazole, indole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinazoline, cinnoline, acridine, phenacene, thiophene, benzothiophene, fliran, pyran, benzofuran, thiazole, benzthiazole, phenothiazine, pyrrolopyrimidine, furopyridine and thienopyrimidine, more preferably pyridine, thiophene, benzothiophene, thiazole, benzothiazole, quinoline, quinazoline, cinnoline, pyrrolopyrimidine, pyrimidine, furopyridine and thienopyrimidine.
  • heterocyclic group preferably,
  • heterocyclic groups for use in the present invention may preferably include pyrrolidine, piperidine, morpholine, pyrrole, pyridine, pyridone, pyrimidine, imidazole, indole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinazoline, cinnoline, acridine, phenacene, thiophene, benzothiophene, furan, pyran, benzofuran, thiazole, benzothiazole, phenothiazine and carbostyryl, alternatively, pyrrolidine, piperidine, morpholine, pyrrole, pyridine, pyridine-N-oxide, thiophene, benzothiophene, thiazole, benzothiazole, quinoline, quinazoline, cinnoline, benzofuran, indole, and carbostyryl, and further alternatively,
  • bicyclic or tricyclic heterocyclic groups which may be used in the present invention include indole or 2,3-dihydroindole, isoindole, indolizine, purine, indazole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazoline, perimidine, phenanthroline, phenacene, benzimidazole, pyrrolopyridine, pyrrolopyrimidine and pyridopyrimidine; sulfur-containing aromatic heterocycles such as thiophene and benzothiophene; oxygen-containing aromatic heterocycles such as cyclopentapyran, benzofuran and isobenzofuran; and
  • substituted shall mean substituted at a carbon (or nitrogen) position within context, hydroxyl, carboxyl, cyano (C ⁇ N), nitro (NO 2 ), halogen (preferably, 1 , 2 or 3 halogens, especially on an alkyl, especially a methyl group such as a trifiuoromethyl), thiol, an optionally substituted alkyl, alkene or alkyne group (preferably, CpC 6, C 2 -C 6 , more preferably C1-C3, C 2 -C 3 ), optionally substituted aryl (especially optionally substituted phenyl or benzyl), optionally substituted heterocyclic (especially optionally substituted heteroaryl for example, pyridinyl (2-, 3-, 4-), pyrimidinyl, thienyl (2- or 3-), furanyl (2- or 3-), alkoxy (preferably, C 1 -C 6 alkyl or aryl), optionally substituted C 2 -Cj 2
  • dialkanolamine alkanol (preferably, Ci-C 6 alkyl or aryl), or alkanoic acid (preferably, CpC 6 alkyl or aryl), optionally substituted carboxyamide (carbonyl attached to the carbon atom with one or two substituents on the amine group- preferably H or an optionally substituted Ci-C 6 alkyl group), amido group (amine group with H or C 1 -C 3 alkyl group attached to the carbon atom with a single group, preferably H or an optionally substituted C 1 -C 6 alkyl group on the keto group) or an optionally substituted urethane group (with either the amine or the 0-carboxy group attached to a carbon atom to which the urethane is a substituent- the amine group being substituted with one or two H or one or two C 1 -C 6 alkyl groups), -O-alkyl aryl, -O-alkenyl aryl, -O- alkynyl ary
  • the term "substituted” shall mean within the context of its use alkyl, alkoxy, halogen, hydroxyl, carboxylic acid, cyano, ether, ester, acyl, nitro, amine (including mono- or di- alkyl substituted amines) and amide, as otherwise described above. Any substitutable position in a compound according to the present invention may be substituted in the present invention. Preferably no more than 5, more preferably no more than 3 substituents are present on a single ring or ring system.
  • the term "unsubstituted” shall mean substituted with one or more H atoms. It is noted that in describing a substituent, all stable permutations of the substituent are intended.
  • Preferred substituents for use in the present invention include, for example, F, Cl, CN, NO 2 , NH 2 , NHCH 3 , N(CH 3 ) 2 , CH 3 , CH 2 OH, COOH, CH 2 CH 3 , CH 2 OCH 3 , CF 3 , COCH 3 , CO 2 CH 3 , CH 2 CO 2 CH 3 , optionally substituted naphthyl (including 1-naphthyl), thienyl, optionally substituted furanyl (especially CH 2 OCH 2 -furanyl), optionally substituted 2- or 3- pyridyl (especially CH 2 -pyridyl or CH 2 ⁇ CH 2 -pyridyl), optionally substituted isoquinoline (especially 4-isoquinoline), optionally substituted pyrimidyl and optionally substituted phenyl, including benzyl (CH 2 OCH 2 -phenyl).
  • MIF macrophage migration inhibitory factor
  • Accession number EMBL Z23063 describes the nucleic acid sequence encoding human MIF (Bernhagen et al., Biochemistry 33:14144-14155 (1994)).
  • An active fragment of MIF may comprise a fragment or a portion of the MIF protein encoding the tautomerase enzymatic activity of MIF, or a fragment that is capable of binding CD74.
  • MIF agonist refers to any agent that mimics, activates, stimulates, potentiates or increases the biological activity of MIF.
  • a MIF agonist may be MIF or a fragment thereof; an agent that mimics MIF (such as a small molecule); an agent that increases or enhances the expression of MIF, CD74 or CD44; an agent that enhances the binding of MIF to CD74; an agent than enhances the interaction between CD74 and CD44 (including, without limitation, a bivalent agent).
  • the "biological function of MIF” refers to the ability of MIF to carry out one or more of the biological functions of MIF including, without limitation, sustaining immune cell survival or activation, promoting cytokine promotion, down-regulating CCR5, binding to CD74, activating MAP kinase signaling (e.g., ERK1/2, JNK, and SAPK MAP kinase signaling), inhibiting p53, acting as a tautomerase, and/or acting as a thiol reductase.
  • MAP kinase signaling e.g., ERK1/2, JNK, and SAPK MAP kinase signaling
  • MIF antagonist refers to any agent that attenuates, inhibits, opposes, counteracts, or decreases the biological activity of MIF.
  • a MIF antagonist may be an agent that inhibits or neutralizes MIF activity (including, without limitation, small molecules and anti-MIF antibodies); an agent that inhibits or decreases the expression of MIF (including, without limitation, an antisense molecule); an agent that inhibits or decreases the expression of the CD44 receptor (including, without limitation, an antisense molecule or an RNAi molecule); an agent that prevents the binding of MIF to CD74 (including, without limitation, an anti-CD74 antibody or an anti-MIF antibody or a fragment thereof); an agent that prevents the interaction between CD74 and CD44 (such as an anti-CD74 antibody or an anti-CD44 antibody or a fragment thereof); or an agent that prevents the interaction between CD74 and CD44.
  • Examples of such molecules are fragments of CD74 and CD44, such as soluble fragments of such receptors.
  • MIF antagonists have been disclosed previously, see, e.g., U.S. Patent Nos. 6,774,227, Bernhagen et al., Nature 365, 756-759 (1993), Senter et al., Proc Natl Acad Sci USA 99:144-149 (2002); Dios et al., J. Med. Chem. 45:2410-2416 (2002); Lubetsky et al., J Biol Chem 277:24976-24982 (2002), which are hereby incorporated by reference.
  • Modulate levels of MIF expression means to increase or decrease levels of MIF expression.
  • treating refers to preventing, slowing, delaying, stopping or reversing the progression of a disease and/or condition.
  • the invention features methods of treating diseases associated with high or low MIF expression comprising administering to a subject in need thereof a therapeutically effective amount of a MIF agonist or a MIF antagonist.
  • the invention comprises administering to a subject having, or at risk of developing, a disease associated with high MIF expression a therapeutically effective amount of a MIF antagonist.
  • the invention comprises administering to a subject having, or at risk of developing, a disease associated with low MIF expression a therapeutically effective amount of a MIF agonist.
  • diseases associated with high MIF expression include, without limitation, diseases caused by infection by a protozoan (for example malaria) fungus, bacteria and viruses, including flavivirus, such as West Nile, Dengue, Japanese encephalitis, St Louis encephalitis, or equine encepahalitis viruses; anemia of chronic disease; asthma and autism spectrum disorder (ASD).
  • diseases associated with low MIF expression include, without limitation, any infection and the diseases caused by infections.
  • the infection is an acute infection.
  • the infection is a bacterial infection.
  • the infection is a viral infection.
  • the infection is a fungal infection.
  • the disease associated with low MIF expression is sepsis.
  • the disease associated with low MIF expression is an infection that leads to a respiratory disease (or a respiratory disease resulting from an infection), including without limitation, infections and diseases caused by gram positive and gram negative bacteria, mycobacteria (such as mycobacterium tuberculosis), fungal infections (e.g., infections of Pneumocystis, Candida, and Histoplasma) and viral infections (e.g., infections of influenza, varicella, and corona virus such as SARS- associated coronoavirus).
  • the disease associated with low MIF expression is meningitis.
  • the disease associated with low MIF expression is influenza.
  • the disease associated with low MIF expression is pneumonia (regardless of whether it is caused by a bacterial, viral or fungal infection).
  • the pneumonia is Community Acquired Pneumonia (CAP).
  • the viral infection is a retroviral infection.
  • the retroviral infection is HIV infection.
  • the disease associated with low MIF expression is infection by a virus or other pathogen that use the CCR5 receptor for infection, including, without limitation, HIV-I, HCV, Epstein-Barr Virus, and Yersinia pestis.
  • the invention provides a method of treating anemia of chronic disease comprising administering to a subject a therapeutically effective amount of a MIF antagonist.
  • the subject has or is at risk of developing anemia of chronic disease.
  • the subject has anemia of chronic disease and the subject is not responsive to erythropoietin (EPO) prior to the administration of the MIF antagonist.
  • EPO erythropoietin
  • the subject is has a genotype that is associated with high MIF expression.
  • the subject is Caucasian.
  • Anemia of chronic disease may result from, among other conditions, pathogenic infection (e.g., a malaria infection), cancer, autoimmune diseases or disorders (lupus erythematosis, arthritis, including rheumatoid arthritis, kidney diseases or disorders, organ transplant rejection and aging.
  • pathogenic infection e.g., a malaria infection
  • cancer e.g., a malaria infection
  • autoimmune diseases or disorders lupus erythematosis, arthritis, including rheumatoid arthritis, kidney diseases or disorders, organ transplant rejection and aging.
  • the invention provides a method of treating anemia of chronic disease regardless of its cause.
  • the invention provides a method of treating anemia of chromic disease comprising administering to a subject a therapeutically effective amount of a MIF antagonist in combination with one or more other agents that stimulate erythropoiesis.
  • erythropoiesis-stimulating agents include, without limitation: erythropoietin ("EPO"), iron, folate, vitamin B 12, blood, blood substitute, and plasma or serum that contains a composition with the activity of blood.
  • EPO erythropoietin
  • the invention provides a method of treating anemia of chromic disease, comprising administering to a subject in need thereof a MIF antagonist in combination with EPO.
  • the invention provides a method of treating anemia of chronic disease, comprising administering to a subject a MIF antagonist in combination with a tumor necrosis factor- ⁇ (TNF ⁇ ) antagonist or an interferon (IFN) antagonist (e.g., an IFN ⁇ antagonist) to a subject.
  • TNF ⁇ and IFN ⁇ antagonists include, without limitation, anti-TNF, soluble TNF receptor, anti-IFN ⁇ , soluble IFN ⁇ receptor, p38 MAPK inhibitors, and JAK-STAT inhibitors.
  • the invention also comprises a method of treating malaria comprising administering to a subject in need thereof a MIF antagonist.
  • the subject has malaria or is at risk of developing malaria.
  • the subject is has a genotype that is associated with high MIF expression.
  • the subject is Caucasian.
  • the methods described herein may also comprise the administration of one or more other therapeutic agents.
  • the Use of MIF Agonists to Treat or Prevent Infections also comprises a method of treating an infection comprising administering to a subject a therapeutically effective amount of a MIF agonist.
  • the subject is has a genotype that is associated with low MIF expression.
  • MIF agonists include, without limitation, viral infections (including retroviral infections), bacterial infections, fungal infections, infections leading to respiratory disease, infections with HIV, pneumonia, Community Acquired Pneumonia (CAP), meningitis, and influenza, hi certain embodiments, a MIF agonist is used to treat pathogenic infections during acute stages of infection, including during a flare-up of the infection, during a change of therapy, when signs of resistance to therapy are displayed in the subject, or as an early intervention.
  • viral infections including retroviral infections
  • bacterial infections including fungal infections
  • infections leading to respiratory disease infections with HIV, pneumonia, Community Acquired Pneumonia (CAP), meningitis, and influenza
  • CAP Community Acquired Pneumonia
  • a MIF agonist is used to treat pathogenic infections during acute stages of infection, including during a flare-up of the infection, during a change of therapy, when signs of resistance to therapy are displayed in the subject, or as an early intervention.
  • the invention provides a method of treating an infection that leads to a respiratory disease comprising administering to a subject a therapeutically effective amount of a MIF agonist.
  • Infections that lead or may lead to respiratory disease include, without limitation, infections by gram positive and gram negative bacteria, mycobacteria (such as mycobacterium tuberculosis), fungal infections (e.g., infections of Pneumocystis, Candida, and Histoplasm ⁇ ) and viral infections (e.g., infections of influenza, varicella, and corona virus such as SARS-associated coronoavirus).
  • the invention also provides a method of treating a respiratory disease resulting from an infection comprising administering to a subject a therapeutically effective amount of a MIF agonist.
  • the invention provides a method of treating pneumonia in a subject comprising administering to the subject a therapeutically effective amount of a MIF agonist.
  • Microbial infections that lead to pneumonia include, without limitation, bacterial infections (e.g., infections of gram positive bacteria, gram negative bacteria, and mycobacteria such as mycobacterium tuberculosis), fungal infections (e.g., infections of Pneumocystis, Candida, and Histoplasma) and viral infections (e.g., infections of influenza, varicella, and corona virus such as SARS-associated coronoavirus).
  • the invention provides a method of treating a retroviral infection comprising administering to a subject a therapeutically effective amount of a MIF agonist.
  • the invention provides a method of treating HIV infection comprising administering to a subject a therapeutically effective amount of a MIF agonist.
  • the invention also comprises the use of a MIF agonist as an immunoadjuvant.
  • the methods described herein may also comprise the administration of one or more other therapeutic agents, including without limitation anti-bacterial agents, anti-fungal agents and anti-microbial agents.
  • anti-viral agents include, without limitation, reverse transcriptase inhibitors such as, for example, zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, nevirapine, delavirdine, and efavirenz; protease inhibitors such as, for example, saquinavir, ritonavir, nelfinavir, indinavir, amprenavir, and lopinavir; agents for treating herpes viruses such as, for example, acyclovir, valacyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, and cidolovir; and, agents for treating influenza such as, for example, oseltamivir, amantadine, rimatadine, and zanamivir.
  • anti-bacterial agents include, without limitation, penicillins, cephalosporins,
  • the invention provides a method of attenuating the expression of CCR5 mRNA or protein, comprising the use of a MIF agonist.
  • a MIF agonist for example, in one embodiment, cells expressing a CCR5 receptor are contacted with a MIF agonist wherein said contacting results in the attenuation of the expression of CCR5 mRNA or protein.
  • the invention provides a method of inhibiting the life-cycle of a virus in a subject infected with said virus or at risk of being infected with said virus, wherein the virus uses the CCR5 as a receptor, administering to the subject a MIF agonist.
  • the pathogen that uses the CCR5 for infection is HIV-I .
  • the "inhibiting the life cycle of a virus” includes, inhibiting viral replication, inhibiting viral infection, latency and oncogenesis.
  • the invention provides a method of treating HIV infection in a subject infected or at risk of being infected with HIV, comprising administering to the subject a MIF agonist.
  • the subject is has a genotype that is associated with low MIF expression.
  • a MIF agonist is administered to a subject during acute HFV infection or during a flareup.
  • the methods described herein may also comprise the administration of one or more other therapeutic agents.
  • the methods described herein comprise the administration of a MIF agonist in combination with anti-viral agents.
  • anti-viral agents include, without limitation, reverse transcriptase inhibitors such as, for example, zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, nevirapine, delavirdine, and efavirenz; protease inhibitors such as, for example, saquinavir, ritonavir, nelfinavir, indinavir, amprenavir, and lopinavir; agents for treating herpes viruses such as, for example, acyclovir, valacyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, and cidolovir; and, agents for treating influenza such as, for example, oseltamivir, amantadine, rimatadine, and zanamivir.
  • reverse transcriptase inhibitors such as, for example, zidovudine, didanos
  • the invention provides a method of treating HIV infection in a subject comprising administering to the subject a therapeutically effective amount of a MIF agonist.
  • the HIV infection is at an acute stage.
  • the method further comprises administering to the subject another anti-viral agent.
  • the invention provides a method of modulating the biological function of MIF, comprising the use of an agent that interacts modulates the interaction of CD44 with CD74.
  • the invention provides a method of attenuating the biological function of MIF, comprising the use of an agent that inhibits the interaction between CD44 and CD74.
  • the agent may be any agent.
  • the agent is selected from the group consisting of: a fragment of CD44, an extracellular fragment of CD44, an agent that binds CD44, an antibody or fragment thereof that binds to CD44, a small molecule, a small molecule mimic of chondroitin sulfate, heparin and a macromolecular mimic of chondroitin sulphate.
  • the invention provides a method of attenuating the biological function of MIF, comprising the use of an agent that inhibits the expression of CD44.
  • the agent may be any agent.
  • the agent is an siRNA or antisense polynucleotide that targets CD44.
  • the invention provides a method of increasing the biological function of MIF, comprising the use of an agent that increases the interaction between MIF, CD44 and CD74. In one embodiment, the invention provides a method of increasing the biological function of MIF, comprising the use of an agent that increases the interaction between CD44 and CD74.
  • a "disease associated with high MIF expression” or a “disease associated with low MIF expression” is a disease associated with high or low MIF expression, respectively. This association can be established using well known methods.
  • diseases that are associated with high MIF expression include: autoimmunity, cancer, anemia of chronic disease, malaria, and asthma.
  • Diseases that are associated with low, or insufficient, MIF expression include: infections (including viral, bacterial and fungal infections) and diseases resulting from, or caused by, infections, including respiratory diseases resulting from any infection, meningitis, pneumonia, CAP, influenza, sepsis, HIV infection, and infection with a pathogen that uses CCR5 as a receptor (such as HIV-I, Hepatitis C Virus (HCV), Epstein-Barr Virus, or Yersinia pestis).
  • infections including viral, bacterial and fungal infections
  • Representative cancers which may be treated using compounds according to the present invention include, for example, stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/CNS, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, leukemia, melanoma, non-melanoma skin cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, glioma, teratoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, kidney cancer and other lymphoma, among others.
  • Compounds according to the present invention may be administered in combination with additional anticancer agents.
  • anticancer agents include, for example, antimetabolites, inhibitors of topoisomerase I and II, alkylating agents and microtubule inhibitors (e.g., taxol).
  • Specific anticancer compounds for use in the present invention include, for example, adriamycin aldesleukin; alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine; anastrozole; arsenic trioxide; Asparaginase; BCG Live; bexarotene capsules; bexarotene gel; bleomycin; busulfan intravenous; busulfan oral; calusterone; capecitabine; carboplatin; carmustine; carmustine with Polifeprosan 20 Implant; celecoxib; chlorambucil; cisplatin; cladribine; cyclophosphamide; cytarabine; cytarabine liposomal; dacarbazine; dactinomycin; actinomycin D; Darbepoetin alfa; daunorubicin liposomal; daunorubicin, daunomycin; Den
  • a “disease associated with high MIF expression” or a “disease associated with low MIF expression” also includes a disease in which an endogenous MIF response to treatment causes or exacerbates the disease.
  • a “disease associated with high MIF expression” includes an inflammatory or atherosclerotic lesion or a disorder that proves resistant to steroid treatment.
  • anemia of chronic disease refers to anemia that is immune driven.
  • Anemia of chronic disease also known as “anemia of inflammation.” This condition can result from a condition selected from the group consisting of: a pathogenic infection, cancer, an autoimmune disease or disorder, a kidney disease or disorder, organ transplant rejection, and aging. See, e.g., Weiss and Goodnought, "Anemia of Chronic Disease", N. Engl. J. Med. 352(10): 1011-23 (2005).
  • the term "therapeutically effective amount” refers to the amount of a MIF agonist or antagonist (isolated or recombinantly produced), or a composition comprising a MIF agonist or antagonist, that is in sufficient quantities to treat a subject having, or at risk of developing, a disease associated with high or low MIF expression, or to treat a disease associated with high or low MIF expression itself.
  • an effective amount is sufficient to delay, slow, or prevent the onset or progression of a disease associated with high or low MIF expression, or related symptoms.
  • pharmaceutically acceptable refers to a carrier, additive or excipient which is not unacceptably toxic to the subject to which it is administered. Pharmaceutically acceptable excipients are described at length by E. W. Martin, in “Remington's Pharmaceutical Sciences", among others well-known in the art.
  • a "pharmaceutically acceptable salt” of the present compound generally refers to pharmaceutically acceptable salts form of a compound which can form a salt, because of the existence of for example, amine groups, carboxylic acid groups or other groups which can be ionized in a sample acid-base reaction.
  • a pharmaceutically acceptable salt of an amine compound such as those contemplated in the current invention, include, for example, ammonium salts having as counterion an inorganic anion such as chloride, bromide, iodide, sulfate, sulfite, nitrate, nitrite, phosphate, and the like, or an organic anion such as acetate, malonate, pyruvate, propionate, fumarate, cinnamate, tosylate, and the like.
  • Certain compounds according to the present invention which have carboxylic acid groups or other acidic groups which may may form pharmaceutically acceptable salts, for example, as carboxylate salts, are also contemplated by the present invention.
  • aspects of the present invention include compounds which have been described in detail hereinabove or to pharmaceutical compositions which comprise an effective amount of one or more compounds according to the present invention, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
  • pharmaceutically acceptable derivative is used throughout the specification to describe any pharmaceutically acceptable prodrug form (such as an ester or ether or other prodrug group) which, upon administration to a patient, provides directly or indirectly the present compound or an active metabolite of the present compound.
  • inhibitory effective concentration or “inhibitory effective amount” is used throughout the specification to describe concentrations or amounts of compounds according to the present invention which substantially or significantly modulate levels of MIF expression.
  • preventing effective amount is used throughout the specification to describe concentrations or amounts of compounds according to the present invention which are prophylactically effective in preventing, reducing the likelihood of infection or delaying the onset of a disease associated with high or low levels of MIF expression.
  • inhibitory effective amount or preventive effective amount also generally fall under the rubric "effective amount”.
  • co-administration is used to describe the administration of two active compounds, in this case a compound according to the present invention, in combination with an additional MIF-modulating agent or other biologically active agent, in effective amounts.
  • co-administration preferably includes the administration of two active compounds to the patient at the same time, it is not necessary that the compounds actually be administered at the exact same time, only that amounts of compound will be administered to a patient or subject such that effective concentrations are found in the blood, serum or plasma, or in the pulmonary tissue at the same time.
  • a composition comprising a MIF agonist or antagonist is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of a disease or condition associated with high or low MIF expression, or related symptoms, or to reverse a disease or condition associated with high or low MIF expression.
  • an effective amount of a composition for treating a subject who has been diagnosed or predicted to be at risk for developing a disease or condition associated with high or low MIF expression is a dose or amount that is in sufficient quantities to treat a subject or to treat the disorder itself.
  • MIF agonists and antagonists may be formulated with a pharmaceutically acceptable carrier.
  • a MIF agonist or antagonist can be administered alone or as a component of a pharmaceutical formulation (therapeutic composition).
  • the MIF agonist or antagonist may be formulated for administration in any convenient way for use in human medicine.
  • the therapeutic methods of the invention include administering the composition topically, systemically, or locally.
  • therapeutic compositions of the invention may be formulated for administration by, for example, injection (e.g., intravenously, subcutaneously, or intramuscularly), inhalation or insufflation (either through the mouth or the nose) or oral, buccal, sublingual, transdermal, nasal, or parenteral administration.
  • the compositions described herein may be formulated as part of an implant or device.
  • the therapeutic composition for use in this invention is in a pyrogen-free, physiologically acceptable form.
  • the composition may be encapsulated or injected in a viscous form for delivery to the site where the target cells are present.
  • therapeutically useful agents may optionally be included in any of the compositions described herein.
  • therapeutically useful agents may, alternatively or additionally, be administered simultaneously or sequentially with a MIF agonist or antagonist according to the methods of the invention.
  • compositions comprising a MIF agonist or antagonist can be administered orally, e.g., in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in- water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of an agent as an active ingredient.
  • An agent may also be administered as a bolus, electuary or paste.
  • one or more compositions comprising a MIF agonist or antagonist may be mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7)
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents,
  • Suspensions in addition to the active compounds, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • compositions disclosed herein may be administered topically, either to skin or to mucosal membranes.
  • the topical formulations may further include one or more of the wide variety of agents known to be effective as skin or stratum corneum penetration enhancers. Examples of these are 2-pyrrolidone, N-methyl-2-pyrrolidone, dimethylacetamide, dimethylformamide, propylene glycol, methyl or isopropyl alcohol, dimethyl sulfoxide, and azone. Additional agents may further be included to make the formulation cosmetically acceptable. Examples of these are fats, waxes, oils, dyes, fragrances, preservatives, stabilizers, and surface active agents. Keratolytic agents such as those known in the art may also be included. Examples are salicylic acid and sulfur.
  • Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
  • the ointments, pastes, creams and gels may contain, in addition to a MIF agonist or antagonist, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to a MIF agonist or antagonist, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • compositions suitable for parenteral administration may comprise a MIF agonist or antagonist in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • a composition comprising a MIF agonist or antagonist may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.
  • Benzooxazolone derivatives of the invention can be prepared as follows.
  • reaction mixture was purified by column chromatography, eluting with n-hexane:AcOEt (1 :1) to yield 4- [l,3]dioxolan-2-yl-2-nitro-phenol (1.0 gm, 83%) as a yellow solid.
  • the reaction mixture was purified by chromatography, eluting with n-hexane: AcOEt (4:6) to obtain 5-[l,3]dioxolan-2-yl-3H-benzooxazol-2-one (220 mg, 66%) as a white solid.
  • 5-[l,3]dioxolan-2-yl-3H-benzooxazol-2-one 100 mg, 0.48 mmol
  • K 2 CO 3 132mg, 0.96 mmol
  • 3-methoxybenzyl bromide 132 mg, 0.48 mmol
  • Methyl 2,2,2-trichloroacetamide (1.83 gm, 17 mmol) was added to a solution of o- phenylenediamine (3 gm, 17.0 mmol) in acetic acid, which was then stirred at room temperature for 1 h. Water was added (20 mL) to the mixture, and resultant precipitate was filtered. The filtrate was washed with water and dried under vacuum to afford 2- Trichloromethyl-lH-benzoimidazole (3.4 gm, 14.4 mmol, 85%) as a dark yellow color solid.
  • the tautomerase assay monitored the keto/enol interconversion for /7-hydroxyphenylpyruvate (HPP) catalyzed by MIF (Stamps, S. L., (2000), Mechanism of the Phenylpyruvate Tautomerase Activity of Macrophage Migration Inhibitory Factor: Properties of the PlG, Pl A, Y95F, and N97A Mutants Biochemistry 39, 9671-9678).
  • HPP keto/enol interconversion for /7-hydroxyphenylpyruvate
  • the tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277, 24976-24982).
  • a compound may appear active in one tautomerase assay and not in the other; in fact, ISO-I is inactive in the HPP tautomerase assay.
  • the biologically more significant assay is a "capture" assay using immobilized, recombinant MIF receptor ectodomain and biotinylated recombinant MIF (Leng, L., et al. (2003), MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467-1476). This allows measurement of the inhibition or enhancement of the binding of MIF to its receptor induced by an addend.
  • Table 1 also notes that ISO-I is inactive in the capture assay, while a biologically neutralizing anti-MIF antibody is a 0.4 ⁇ M inhibitor.
  • Another reference compound, 4-iodo-6- phenylpyrimidine (4-IPP) also is inactive in the capture assay, but is a 4.5- ⁇ M inhibitor in the HPP tautomerase assay.
  • 4-IPP has recently been licensed by Advanced Cancer Therapeutics from the University of Louisville; the press release notes that "4-IPP, a novel small molecule compound, exhibits anti-tumor activity by blocking tumor-specific angiogenesis, and thus far has demonstrated a favorable safety profile in laboratory studies.
  • this chemokine As a macrophage migration inhibitory factor (MIF), this chemokine promotes multiple pro-angiogenic growth factors (VEGF and IL-8) and contributes to tumor cell division, metastases and tumor vascularization (i.e., angiogenesis).
  • VEGF and IL-8 pro-angiogenic growth factors
  • angiogenesis tumor vascularization
  • 4-IPP has subsequently been evaluated for its potential to address various unmet medical needs in autoimmune related diseases such as Rheumatoid Arthritis, Lupus and Multiple Sclerosis.”
  • autoimmune related diseases such as Rheumatoid Arthritis, Lupus and Multiple Sclerosis.
  • 4-IPP as an unattractive drug candidate owing to anticipated off-target activities associated with the highly electrophilic 4-iodo-pyrimidine subunit.
  • HPP assay used was adapted to the microtiter plate format.
  • Human MIF protein was purified according to Bernhagen et al. Biochemistry, 33:14144-14155, 1994. Dilutions of the enzyme were prepared in 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.5.
  • HPP was obtained from Aldrich. A stock solution of 60 mM HPP in ethanol is prepared and kept for maximally 4 hours on ice. The working solution (600 ⁇ M) of the substrate was prepared by diluting an aliquot of the stock solution with 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.5.
  • UV-transparent microtiter plates (96- well) were obtained from Corning (Cat#3635).
  • Inhibitor and enzyme solutions were pipetted manually using an Eppendorf 12- channel pipette. Addition of substrate to start the reaction was performed with an Igel 96 pipetting station (OpaUena, Jena, Germany), which allows simultaneous addition of fluid to all 96 wells of the plates. Optical density (OD) was determined using a SPECTRAmax 250 reader (Molecular Devices). The reader was operated with the SoftmaxPro 2.6.1 software. Assay: Three wells of the microtiter plates were filled with buffer only, to allow for blanking.
  • test wells were pipetted consecutively: 50 ⁇ l inhibitor dilution (or buffer for control), 50 ⁇ l enzyme dilution (55 nM; final concentration in assay: 18.3 nM), 50 ⁇ .l freshly diluted substrate working solution (600 ⁇ .M; final concentration: 200 ⁇ .M). The last step was performed using the 96-channel pipetting device. The plate was then immediately (i.e. within a few seconds) transferred manually to the SPECTRAmax 250 reader and the optical density was determined (310 nm). From the data obtained, IC 50 values were calculated using Excel® and XLfit® software.
  • Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. Biochemistry 38, 7346-54.
  • the macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase.
  • MIF macrophage migration inhibitory factor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.

Description

MIF MODULATORS Field of the Invention
The present invention relates to novel heterocyclic compounds, pharmaceutical compositions and their use in modulating levels of MIF expression and in treating disorders associated with high or low levels of MIF expression.
Related Applications/Research Support
This application claims the benefit of priority of provisional application serial number US61/189,327, entitled "MIF Modulators", filed August 18, 2008, the entire contents of which is incorporated by reference herein.
The invention described herein was supported, in whole or in part, by the National Institute of Health Grant Nos. AI043210, AR049610, AR050498, and GM032136. Consequently, the United States government has certain rights in the invention.
Background of the Invention
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that is released by T-cells and macrophages. It is viewed to play a key role in a wide range of diseases including rheumatoid arthritis, sepsis, atherosclerosis, asthma, and acute respiratory distress syndrome. MIF also is involved in cell proliferation and differentiation, and anti-MIF antibodies suppress tumor growth and angiogenesis. The biology of MIF and potential biomedical significance of MIF-inhibition are striking, as reviewed elsewhere. Orita, et al., (2002), Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors, Curr. Pharm. Res. 8, 1297-1317 ("Orita 2002"); Lolis, et al. (2003), Macrophage migration inhibitory factor, Expert Opin. Therap. Targets 7, 153-164; Morand, et al., (2006), MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nature Rev. Drug Disc. 5, 399-411. The crystal structure for MIF, which was solved by Prof. Elias Lolis at Yale, revealed a new structural superfamily (Sun, H. et al. (1996) Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc. Nat. Acad. Sci. USA 93, 5191-5196; Lolis, E. & Bucala, R. (1996) Crystal structure of macrophage migration inhibitory factor (MIF), a glucocorticoid-induced regulator of cytokine production, reveals a unique architecture. Proc. Assoc. Amer. Physicians 108, 415-9); the 114-residue MIF monomer has a β/α/β motif and three monomers associate to form a symmetrical trimer. The trimer is toroidal with a solvent-filled central channel. MIF was also found to show structural homology to two prokaryotic tautomerases, and phenylpyruvate and D-dopachrome were discovered to be MIF tautomerase substrates. Rosengren, E.; et al., (1996) The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Molec. Med. 2, 143-149; Rosengren, E.; et al. (1997), The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett. 417, 85-8.
Figure imgf000003_0001
Though L-dopachromes are substrates for a response mechanism of invertebrates to microbial invasion, the catalytic activity of mammalian MIF is likely vestigial. Site-directed mutagenesis and crystallography have identified the MIF active site, and mechanisms for the tautomerase activity have been proposed with key roles for Prol as a base and Lys32 as a proton donor (Lubetsky, J. et al. (1999), Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. Biochemistry 38, 7346-54; Lolis, et al. (2003), Macrophage migration inhibitory factor, Expert Opin. Therap. Targets 7, 153-164). Each MIF trimer has three tautomerase active sites, which are well defined cavities located at the interfaces of the monomer subunits. There is also evidence that the interaction of MIF with its receptor, CD74, occurs in this vicinity and MIF inhibition is often directly competitive with MIF-CD74 binding. Senter, P. D., et al, (2002) Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Nat. Acad. Sci. USA 99, 144-9 ("Senter 2002"). However, some potent tautomerase inhibitors do not inhibit the biological activity of MIF (Senter 2002).
Discovery of small molecule inhibitors of MIF is clearly important to provide further probes into the biology of MIF and potential therapeutic agents for MIF-related diseases. As reviewed in Orita 2002, initial efforts provided some dopachrome (Zhang, X. & Bucala, R. (1999), Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs. Bioorg. Med. Chem. Lett. 9, 3193-3198), glutathione, and hydroxycinnamate analogs in the μM to mM range. Subsequently, a virtual screening exercise with the DOCK program on the Available Chemicals Directory, followed by purchase and assaying of 524 compounds delivered 14 leads with K1 values below 10 μM. However, the diversity is low since all 14 compounds are coumarin derivatives or close analogs (Orita, M., et al. (2001). Coumarin and Chromen-4-one Analogues as Tautomerase Inhibitors of Macrophage Migration Inhibitory Factor: Discovery and X-ray Crystallography. J. Med. Chem. 44, 540-547). Coumarins are generally viewed as poor drug leads owing to their promiscuity as protein binders. These authors also reported a crystal structure for a 7- hydroxycoumarin derivative complexed with MIF. Shortly thereafter, the activities of several phenyl-dihydroisoxazoles were published along with the crystal structure for the MIF complex with the most potent one, ISO-I (Lubetsky, J. B. et al. (2002), The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277, 24976-24982). A key feature in the X- ray structures is a hydrogen bond between the phenolic OH and the side-chain CO of Asn97, which forms a backstop for the active site channel. Further optimization enhanced the potency from 7 μM for (φ-ISO-1 to 550 nM for (R)-Il (Cheng, K. F. & Al- Abed, Y. (2006) Critical modifications of the ISO-I scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg. Med. Chem. Lett. 16, 3376- 3379).
Figure imgf000004_0001
PCT WO2006045505 discloses MIF inhibitors. The MIF inhibitors of PCT WO2006045505 are 3,4-dihydro-benzo[e][l,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C3-8)cycloalkyl, (Cl-4)alkyl(C3-8)cycloalkyl, (C6-18)aryl or (C6-18)aryl(Cl-4)alkyl. PCT WO2007070961 discloses MIF-inhibiting benzimidazolone analogues and derivatives.
Given the extent and severity of MIF-associated disorders, there is a continuing need for novel compounds, pharmaceutical compositions, and methods of treatment that modulate levels of MIF expression. Objects of the Invention
Various objects of the invention relate to chemical compounds which modulate Macrophage migration inhibitory factor (MIF).
Additional objects of the invention relate to pharmaceutical compounds, methods of modulating MIF and/or treating disease states and/or conditions where MIF modulation (especially agonist and antagonist activity is relevant).
Any one or more of these and/or other aspects of the invention may be readily gleaned from a review of the description of the invention which follows.
Brief Description of the Invention
The present inventors have pursued the development of novel inhibitors and agonists for the interaction of MIF with its receptor, CD74. The work combines computer-aided compound design, synthetic organic chemistry, and biological assaying. Lead generation proceeded by both de novo design and molecular docking of large libraries of commercially available compounds. See Jorgensen, W. L. (2004), The Many Roles of Computation in Drug Discovery. Science 303, 1813-1818, and Jorgensen W. L., Accounts of Chemical Research, Vol. 42, No. 6, pp. 724-733 (June, 2009), relevant portions of which are incorporated by reference herein.
Accordingly, in one embodiment, the present invention is directed to bicyclic compounds according to the chemical structure (I):
Figure imgf000005_0001
(I)
where X is O, S, N-R™1 or CRXC1RXC2; Y is N-R^' or CR^R^ and
Z is O, S, N-R2*1 or CRZC1RZC2 , with the proviso that at least one of X or Z is N-R™1 and X and Z are other than O, when Y is O;
R™1 is absent (N is -N=, thus forming a double bond with an adjacent atom), H or an optionally substituted Ci-C8 alkyl, alkene or alkyne group, an optionally substituted C1-C7 acyl group, an optionally substituted (CH2)J -phenyl group or an optionally substituted
(CH2)m-heterocyclic (preferably heteroaryl) group;
R™1 is absent, H, an optionally substituted C1-C8 alkyl, alkene or alkyne group, an optionally substituted Ci-C8 acyl group, an optionally substituted (CH2)J -phenyl group or an optionally substituted (CH2)m-heterocyclic (preferably heteroaryl) group;
R2*1 is absent, H, an optionally substituted Ci-C8 alkyl, alkene or alkyne group, an optionally substituted C]-C8 acyl group, an optionally substituted (CH2)j-phenyl group or an optionally substituted (CH2)m-heterocyclic (preferably heteroaryl) group;
RXC1 is absent (C is -C=, thus forming a double bond with an adjacent atom), H, an optionally substituted Ci-C3 alkyl, or together with RXC2 forms a =0 (keto) or =C group,
(preferably RXC1 is absent);
RXC2 is H, halogen, cyano, an optionally substituted C1-Cg alkyl, alkene or alkyne group
(preferably R is an optionally substituted C1-C3 group when R is an optionally substituted Ci -C3 group), an optionally substituted Ci-C8 acyl group, an optionally substituted
C2-C8 ester (hydroxyester) or carboxyester group, an optionally substituted CpC7 alkoxy group, an optionally substituted C2-C8 ether group, an optionally substituted Cj-C7 amido or carboxamido group, a Ci-C7 urethane or urea group, an optionally substituted (CH2)J -phenyl group or an optionally substituted (CH2)m-heterocyclic (preferably heteroaryl) group, or together with RXC1 forms a =0 (keto) or =C group, which is optionally substituted with a Q-
C6 alkyl group, an optionally substituted (CH2)J -phenyl group or an optionally substituted
(CH2)m-heterocyclic (preferably heteroaryl) group;
RYC1 is absent, H, an optionally substituted Ci-C3 alkyl, or together with RYC2 forms a =0
(keto) or =C which is optionally substituted with a heterocyclic group;
RYC2 is H, halogen, cyano, an optionally substituted Ci-C8 alkyl, alkene or alkyne group
(preferably R is an optionally substituted Ci-C3 group when R is an optionally substituted Cj-C3 group), an optionally substituted CpC7 acyl group, an optionally substituted
C2-C8 ester or carboxyester group, an optionally substituted Ci -Qo alkoxy group, an optionally substituted C2-C8 ether group, an optionally substituted Ci-C7 amido or carboxamido group, a Cj-C7 urethane or urea group, an optionally substituted (CH2)J -phenyl group or an optionally substituted (CH2)m-heterocyclic (preferably heteroaryl) group, or together with RYC1 forms a =0 (keto) or =C group, which is optionally substituted with a Ci-
C6 alkyl group, an optionally substituted (CH2)J -phenyl group or an optionally substituted
(Ctym-heterocyclic (preferably heteroaryl) group;
Rzcι is absent, H, an optionally substituted C1-C3 alkyl, or together with RZC2 forms a =0
(keto) group or a =C group, (preferably RZC1 is absent);
RZC2 is H, halogen, cyano, an optionally substituted C1-C8 alkyl, alkene or alkyne group
(preferably R is an optionally substituted Ci -C3 group when R is an optionally substituted Ci-C3 group), an optionally substituted Cj-Cs acyl group, an optionally substituted
C2-C8 ester or carboxyester group, an optionally substituted Ci-C7 alkoxy group, an optionally substituted C2-C8 ether group, an optionally substituted C1-C7 amido or carboxamido group, a Cj-C7 urethane or urea group, an optionally substituted (CH2)J -phenyl group or an optionally substituted (CH2)m-heterocyclic (preferably heteroaryl) group, or together with RZC1 forms a =0 (keto) or =C group, which is optionally substituted with a C1-
Ce alkyl group, an optionally substituted (CH2)J -phenyl group or an optionally substituted
(CH2)m-heterocyclic (preferably heteroaryl) group;
RA and RB together form an optionally substituted 5, 6 or 7 membered carbocyclic or heterocyclic ring (preferably an optionally substituted 6-membered aromatic or heteroaromatic ring, more preferably an optionally substituted phenyl ring or a heteroaromatic ring containing one nitrogen group, preferably a pyridyl group); each j is independently 0, 1, 2, 3, 4 or 5; and each m is 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
In certain preferred embodiments, the present invention is directed to 6:5 fused ring compounds according to the structure (II):
Figure imgf000007_0001
II Where X, Y and Z are as described above for compound (I); and
Ri and R2 are each independently H, OH, COOH, halogen (F, Cl, Br, I), CN, OH, optionally substituted Ci-C8 alkyl, optionally substituted O-(CrC6)alkyl, SH, S-(d-C6)alkyl, optionally substituted Ci-C8 acyl, optionally substituted C2-C8 ether, optionally substituted C2-C8 ester or carboxyester, optionally substituted C2-C8 thioester, amide optionally subsituted with a C1- C6 alkyl group, carboxyamide optionally substituted with one or two Ci-C6 alkyl or alkanol groups, and amine optionally substituted with one or two C1-C6 alkyl or alkanol groups. Preferably R, and R2 are independently H, CH3, CH2CH3, NH2, NHCH3, N(CH3)2, OH, 0CH3, SH, SCH3, F, Cl, Br or I.
In a more particular aspect of the present invention, compounds according to the present invention have the following chemical structures A-N as depicted below
Figure imgf000008_0001
Figure imgf000008_0002
Figure imgf000008_0003
Figure imgf000009_0001
H
Figure imgf000009_0002
K
Figure imgf000009_0003
M N
wherein R™1, Rwι, RYC2 and RZC2 are as described above for compound (II);
R1, R2, Z1, Z2, Z3, Z4 and Z5 are each independently H, hydroxyl, optionally substituted CpCg alkyl, alkene or alkyne group, optionally substituted Ci-C8 acyl group, optionally substituted
C2-C8 ether, optionally substituted or C2-C8 ester group, an optionally substituted C5-C11
(CH2)j-carbocyclic group wherein said carbocyclic group forms an optionally substituted 5, 6 or 7-membered ring (preferably, a (CH2)j-phenyl group, where the phenyl group is optionally substituted), or an optionally substituted (CH2)m-heterocyclic group (preferably, an optionally substituted heteroaryl) group, alkoxy, halogen, carboxylic acid, cyano, ether, ester, acyl, nitro, amine (including mono- or di- alkyl substituted amines), or (CH2)j-OH;
R3 is H, an optionally substituted Cj-C6 alkyl group, an optionally substituted O-(Ci-C6)alkyl, an optionally substituted aryl group or heterocyclic group; each j is independently 0, 1, 2, 3, 4 or 5; and each m is 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof. In certain preferred aspects of this invention, R] and R2 are H, CH3, CH2CH3, NH2, NHCH3, N(CH3)2,
OH, OCH3, SH, SCH3, F, Cl, Br or I. R3 is preferably an optionally substituted phenyl group or an optionally substituted heterocyclic group, preferably an optionally substituted heteroaryl group containing a single ring or fused rings (preferably 6:5) such as benzofuran, indole or 2,3-dihydroindole.
In these aspects of the invention compound (A) represents benooxazolone derivatives, including N-benzyl analogs (B). (C) and (D) represent benzoimidazole and benzofuran derivatives, including acyl analogs (E) and (F) where R3 can be a small group or another mono or bicyclic heterocycle such as a benzofuran, indole or 2,3-dihydroindole. Additional representative structures are substituted indoles G, benzopyrazoles H, benzotriazoles J, benzooxazoles K, benzoisoxazoles L, benzothiazolones M, and benzoisothiazolones N, and corresponding compounds with oxygen replacing sulfur or vice versa. In certain embodiments of the compounds of chemical structure (A-N), R1 and R2 are each independently H, CH3, CH2CH3, NH2, NHCH3, N(CH3)2, OH, OCH3, SH, SCH3, F, Cl, Br or I. In other aspects of the invention, Rj and R2 are each independently selected from the group consisting of H, hydroxyl, optionally substituted Ci-C8 alkyl, or (CH2)J-OH; and at least one OfZi-Z5 is a Cj-C6 alkoxy group.
In one embodiment, compounds of the invention provide benzooxazolone derivatives, A, including the iV-benzyl analogs B. Wherein R1, R2 and Zi - Z5 are each independently small aliphatic or heteroatom containing groups; primary examples are H, CH3, CH2CH3, NH2, NHCH3, N(CH3)2, OH, OCH3, SH, SCH3, F, Cl, Br, and I.
In another more particular aspect of the present invention, compounds according to the present invention have the following chemical structure (III):
Figure imgf000010_0001
wherein RA1 and RB1 form a 5, 6 or 7 membered optionally substituted carbocyclic (preferably a phenyl) ring or heterocyclic (preferably, heteroaryl, including a pyridyl) group; R6 is H, an optionally substituted Ci-C8 alkyl, alkene or alkyne group, an optionally substituted C5-CH (CH2)j-carbocyclic group wherein said carbocyclic group preferably forms an optionally substituted 5, 6 or 7-membered ring (preferably, a (CH2)j-aryl group, e.g., a
(CH2)j-phenyl group, wherein the aryl or phenyl group is optionally substituted), or an optionally substituted C4-Cu (CH2)m-heterocyclic group (preferably, an optionally substituted heteroaryl) group; each j is independently 0, 1, 2, 3, 4 or 5; and each m is indepdendently 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
In other preferred embodiments of the compounds of chemical structure (III): (1) R6 is an optionally substituted C5-Cn (CH2)j-carbocyclic group wherein said carbocyclic group forms a 5, 6 or 7-membered ring (preferably, an optionally substituted (CH2)j-phenyl group), or an optionally substituted (CH2)m-heterocyclic group (preferably, an optionally substituted (CH2)m-heteroaryl) group; and (2) RΛI and RB1 form an optionally substituted phenyl or pyridyl group.
In another preferred embodiment of the compounds of chemical structure (III): (1) R6 is an optionally substituted (CH2)j-phenyl group, or an optionally substituted (CH2)m- heterocyclic group (preferably, an optionally substituted (CH2)m-heteroaryl) group; and (2) one of RA1 and RB1 is H and the other is an optionally substituted (CH2)j-phenyl group.
In still another preferred embodiment of the compounds of chemical structure (III): R6 is (a) (CH2)j-phenyl group, which is optionally substituted with no more than three substituents selected from halogen (especially fluoro and chloro), CH3, CH2CH3, CF3, CH2OH, CH2OCH3, OCH3, and CN, or is (b) a (CH2)m-heteroaryl group, which is optionally substituted with no more than three substituents selected from halogen (especially fluoro and chloro), CH3, CH2CH3, CF3, CH2OH, CH2OCH3, OCH3, and CN ; (2) RA1 and RB1 form a phenyl group which is optionally substituted with no more than three substituents selected from halogen (especially fluoro and chloro), CH3, CH2CH3, CF3, CH2OH, CH2OCH3, OCH3, and CN.
Other preferred compounds according to the present invention include the following:
Figure imgf000012_0001
Figure imgf000012_0002
Figure imgf000012_0003
In alternative embodiments according to the present invention, the present invention is directed to a compound according to the chemical structure B:
Figure imgf000012_0004
Where R1 and R2 are each independently selected from H, OH, CN, NO2, halogen (F, Cl, Br, I, preferably Br, Cl or F), Ci-C4 alkyl which is optionally substituted with at least one hydroxyl (from 1 to 3 hydroxyls ) or at least one and preferably .at least three halogens, preferably F, or a -<CH2)j0Ra , -(CH2)jC(O)Ra or -(CH2)j0C(0)Ra group, where Ra is H, a C1-C3 alkyl group which is optionally substituted with at least one hydroxyl group (1 to 3) or at least one halogen, preferably at least three halogen groups, preferably F and j is O, 1, 2 or 3; Z1, Z2, Z3, Z4 and Zs are each independently H, C1-C3 alkyl group which is optionally substituted with at least one hydroxyl group (from 1 to 3) or at least one halogen, preferably at least three halogen groups, preferably F, or a -(CH2)jORa , -(CH2)jC(O)Ra or -(CH2)jOC(O)Ra group, where Ra is H, a C1-C3 alkyl group which is optionally substituted with at least one hydroxyl group (1 to 3) or at least one halogen, preferably at least three halogen groups, preferably F; and j is 0, 1, 2 or 3, or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
In preferred embodiments, Z4 and Z5 are both H. In alternative preferred embodiments, Ri is H, CH3, OCH3, F or OH; R2 is H5CH3 or OH; Z, is H or OCH3; Z2 is H, OH or OCH3; Z3 is H or OCH3; Z4 is H and Z5 is H.
Preferred compounds include a compound where Ri is CH3, R2 is H, Zi is OCH3, Z2 is H, Z3 is H, Z4is H and Z5 is H; a compound where Ri is CH3, R2 is H, Zi is H, Z2 is H, Z3 is H, Z4 is H and Z5 is H; a compound where Ri is H, R2 is OH, Zi is H, Z2 is H, Z3 is OCH3, Z4 is H and Z5 is H; a compound where Rj is F, R2 is H, Zi is H, Z2 is H, Z3 is H, Z4 is H and Z5 is H; a compound where Ri is CH3, R2 is H, Zi is H, Z2 is OH, Z3 is H, Z4 is H and Z5 is H; and a compound where Ri is OH, R2 is H, Zi is OCH3, Z2 is OCH3, Z3 is H, Z4 is H and Z5 is H.
Further embodiments relate to compounds according to the chemical structure:
Figure imgf000013_0001
Where Ri and R2 are each independently selected from H, OH, CN, NO2, halogen (F, Cl, Br, I, preferably Br, Cl or F), Ci-C4 alkyl which is optionally substituted with at least one hydroxyl (from 1 to 3 hydroxyls ) or at least one and preferably at least three halogens, preferably F, or a -(CH2)j0Ra , -(CH2)jC(O)Ra or -(CH2)jOC(O)Ra group, where Ra is H, a Ci -C3 alkyl group which is optionally substituted with at least one hydroxyl group (1 to 3) or at least one halogen, preferably at least three halogen groups, preferably F; and j is O, 1, 2 or 3;
Zi, Z2, Z3, Z4 and Z5 are each independently H, Ci-C3 alkyl group which is optionally substituted with at least one hydroxyl group (from 1 to 3) or at least one halogen, preferably at least three halogen groups, preferably F, or a -(CH2)jORa , -(CH2)jC(O)Ra or -(CH2)j OC(O)R3 group, where Ra is H, a Cj-C3 alkyl group which is optionally substituted with at least one hydroxyl group (1 to 3) or at least one halogen, preferably at least three halogen groups, preferably F; and j is 0, 1, 2 or 3, or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
Preferred compounds include a compound where R1 is H, R2 is F, Z1 is H, Z2 is H, Z3 is Cl, Z4 is H and Z5 is H; a compound where Ri is F, R2 is H, Zi is H, Z2 is H, Z3 is Cl, Z4 is H and Z5 is H; a compound where Ri is F, R2 is H, Zi is H, Z2 is CH2OAc, Z3 is H, Z4 is H and Z5 is H; and a compound where Rj is CN, R2 is H, Zi is H, Z2 is H, Z3 is Cl, Z4 is H and Z5 is H.
In another embodiment according to the present invention, pharmaceutical compositions comprise an effective amount of one or more compounds as described above, optionally in combination with a pharmaceutically acceptable carrier, excipient or additive. Pharmaceutical compositions may also include, in addition to the present compounds, at least one additional compound, including another agent which modulates MIF.
In another embodiment, the present application is directed to the modulation (enhancement or inhibition) of the action of MIF in a patient wherein said method comprises administering an effective amount of a compound according to the present invention in combination with a pharmaceutically acceptable carrier, additive or excipient.
In yet another embodiment, the present application is directed to the treatment of a "disease associated with high MIF expression" or a "disease associated with low MIF expression", as defined hereinafter, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising any one or more of the compounds previously described above, optionally in combination (coadministered) with another active agent, preferably another agent which modulates levels of MIF expression as otherwise disclosed herein.
Pharmaceutical dosage forms comprising the aforementioned novel compounds are also provided by the invention.
Detailed Description of the Invention
The following terms shall be used to describe the present invention. In cases where a term is not specifically defined herein, the term shall be given a common meaning used by those of ordinary skill in the art consistent with the use of that term within the context of describing the present invention. As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a compound" or other element of the present invention includes a plurality (for example, two or more elements) of such elements, and so forth. Under no circumstances is the patent to be interpreted to be limited to the specific examples or embodiments or methods specifically disclosed herein.
The term "compound", as used herein, unless otherwise indicated, refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, optical isomers thereof, as well as pharmaceutically acceptable salts thereof. Within its use in context, the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and/or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds.
The symbol is used in chemical compounds according to the present invention to signify that a bond between atoms is a single bond or double bond according to the context of the bond's use in the compound, which depends on the atoms (and substituents) used in defining the present compounds. Thus, where a carbon (or other) atom is used and the context of the use of the atom calls for a double bond or single bond to link that atom with an adjacent atom in order to maintain the appropriate valence of the atoms used, then that bond is considered a double bond or a single bond.
The term "patient" or "subject" is used throughout the specification within context to describe an animal, generally a mammal and preferably a human, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided. For treatment of those infections, conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal.
The term "effective" is used herein, unless otherwise indicated, to describe an amount of a compound or composition which, in context, is used to produce or effect an intended result, whether that result relates to the treatment of a disorder or condition associated with high or low MIF expression or alternatively, is used to produce another compound, agent or composition. This term subsumes all other effective amount or effective concentration terms which are otherwise described in the present application.
"Hydrocarbon" or "hydrocarbyl" refers to any monovalent (or divalent in the case of alkylene groups) radical containing carbon and hydrogen, which may be straight, branch- chained or cyclic in nature. Hydrocarbons include linear, branched and cyclic hydrocarbons, including alkyl groups, alkylene groups, saturated and unsaturated hydrocarbon groups, including aromatic groups both substituted and unsubstituted, alkene groups (containing double bonds between two carbon atoms) and alkyne groups (containing triple bonds between two carbon atoms). In certain instances, the terms substituted alkyl and alkylene are sometimes synonymous.
"Alkyl" refers to a fully saturated monovalent radical containing carbon and hydrogen, and which may be cyclic, branched or a straight chain. Examples of alkyl groups are methyl, ethyl, n-butyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, isopropyl, 2-methyl- propyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylethyl, cyclohexylethyl and cyclohexyl. Preferred alkyl groups are C1-C6 alkyl groups.
"Alkylene" refers to a fully saturated hydrocarbon which is divalent (may be linear, branched or cyclic) and which is optionally substituted. Preferred alkylene groups are C1-C6 alkylene groups. Other terms used to indicate substitutuent groups in compounds according to the present invention are as conventionally used in the art.
"Aryl" or "aromatic", in context, refers to a substituted or unsubstituted monovalent aromatic radical having a single ring (e.g. , benzene or phpenyl) or multiple condensed rings (e.g., naphthyl, anthracenyl, phenanthryl) and can be can be bound to the compound according to the present invention at any position on the ring(s) or as otherwise indicated in the chemical structure presented. Other examples of aryl groups, in context, may include heterocyclic aromatic ring systems "heteroaryl" groups having one or more nitrogen, oxygen, or sulfur atoms in the ring (moncyclic) such as imidazole, furyl, pyrrole, furanyl, thiene, thiazole, pyridine, pyrimidine, pyrazine, triazole, oxazole, indole or fused ring systems (bicyclic, tricyclic), among others, which may be substituted or unsubstituted as otherwise described herein. The term "cyclic" shall refer to an optionally substituted carbocyclic or heterocyclic group, preferably a 5- or 6-membered ring or fused rings (two or three rings) preferably containing from 8 to 14 atoms. A heterocyclic ring or group shall contain at least one monocyclic ring containing between 3 and 7 atoms of which up to four of those atoms are other than carbon and are selected from nitrogen, sulfur and oxygen. Carbocyclic and heterocyclic rings according to the present invention may be unsaturated or saturated. Preferred carbocyclic groups are unsaturated, and include phenyl groups, among other groups. Preferred heterocyclic groups are heteroaryl or heteroaromatic.
The term "heterocyclic group" as used throughout the present specification refers to an aromatic or non-aromatic cyclic group having 3 to 14 atoms, preferably 5 to 14 atoms forming the cyclic ring(s) and including at least one hetero atom such as nitrogen, sulfur or oxygen among the atoms forming the cyclic ring, which is an aromatic heterocyclic group (also, "heteroaryl" or "heteroaromatic") in the former case and a "non-aromatic heterocyclic group" in the latter case. Specific examples of the heterocyclic group therefore include specific examples of the aromatic heterocyclic group and specific examples of the non- aromatic heterocyclic group, both of which groups fall under the rubric "heterocyclic group" as otherwise described herein. Among the heterocyclic groups which may be mentioned for use in the present invention within context include nitrogen-containing aromatic heterocycles such as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine, pyrazole, imidazole, triazole, tetrazole, indole, isoindole, indolizine, purine, indazole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazoline, perimidine, phenanthroline, phenacene, oxadiazole, benzimidazole, pyrrolopyridine, pyrrolopyrimidine and pyridopyrimidine; sulfur-containing aromatic heterocycles such as thiophene and benzothiophene; oxygen-containing aromatic heterocycles such as furan, pyran, cyclopentapyran, benzofuran and isobenzofuran; and aromatic heterocycles comprising 2 or more hetero atoms selected from among nitrogen, sulfur and oxygen, such as thiazole, thiadiazole, isothiazole, benzoxazole, benzothiazole, benzothiadiazole, phenothiazine, isoxazole, furazan, phenoxazine, pyrazoloxazole, imidazothiazole, thienofuran, furopyrrole, pyridoxazine, furopyridine, furopyrimidine, thienopyrimidine and oxazole. As examples of the "5- to 14-membered aromatic heterocyclic group" there may be mentioned preferably, pyridine, triazine, pyridone, pyrimidine, imidazole, indole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinazoline, cinnoline, acridine, phenacene, thiophene, benzothiophene, fliran, pyran, benzofuran, thiazole, benzthiazole, phenothiazine, pyrrolopyrimidine, furopyridine and thienopyrimidine, more preferably pyridine, thiophene, benzothiophene, thiazole, benzothiazole, quinoline, quinazoline, cinnoline, pyrrolopyrimidine, pyrimidine, furopyridine and thienopyrimidine. The term "heterocyclic group" shall generally refer to 3 to 14- membered heterocyclic groups and all subsets of heterocyclic groups (including non- heteroaromatic or heteroaromatic) subsumed under the definition of heterocyclic group.
Among the heterocyclic groups for use in the present invention may preferably include pyrrolidine, piperidine, morpholine, pyrrole, pyridine, pyridone, pyrimidine, imidazole, indole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinazoline, cinnoline, acridine, phenacene, thiophene, benzothiophene, furan, pyran, benzofuran, thiazole, benzothiazole, phenothiazine and carbostyryl, alternatively, pyrrolidine, piperidine, morpholine, pyrrole, pyridine, pyridine-N-oxide, thiophene, benzothiophene, thiazole, benzothiazole, quinoline, quinazoline, cinnoline, benzofuran, indole, and carbostyryl, and further alternatively, thiazole, quinoline, quinazoline, cinnoline and carbostyryl, among others.
Among the bicyclic or tricyclic heterocyclic groups which may be used in the present invention include indole or 2,3-dihydroindole, isoindole, indolizine, purine, indazole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazoline, perimidine, phenanthroline, phenacene, benzimidazole, pyrrolopyridine, pyrrolopyrimidine and pyridopyrimidine; sulfur-containing aromatic heterocycles such as thiophene and benzothiophene; oxygen-containing aromatic heterocycles such as cyclopentapyran, benzofuran and isobenzofuran; and aromatic heterocycles comprising 2 or more hetero atoms selected from among nitrogen, sulfur and oxygen, such as benzoxazole, benzothiazole, benzothiadiazole, phenothiazine, benzofurazan, phenoxazine, pyrazoloxazole, imidazothiazole, thienofuran, furopyrrole, pyridoxazine, furopyridine, furopyrimidine and thienopyrimidine, among others.
The term "substituted" shall mean substituted at a carbon (or nitrogen) position within context, hydroxyl, carboxyl, cyano (C≡N), nitro (NO2), halogen (preferably, 1 , 2 or 3 halogens, especially on an alkyl, especially a methyl group such as a trifiuoromethyl), thiol, an optionally substituted alkyl, alkene or alkyne group (preferably, CpC6, C2-C6, more preferably C1-C3, C2-C3), optionally substituted aryl (especially optionally substituted phenyl or benzyl), optionally substituted heterocyclic (especially optionally substituted heteroaryl for example, pyridinyl (2-, 3-, 4-), pyrimidinyl, thienyl (2- or 3-), furanyl (2- or 3-), alkoxy (preferably, C1-C6 alkyl or aryl), optionally substituted C2-Cj2 ether (preferably, C2-CiO alkyl ether, alkenylether, alkynyl ether or aryl ether, including phenyl or benzyl ether), acyl (preferably C2-Cg acyl which may include an aryl substituted acyl), optionally substituted ester (preferably, C1-C6 alkyl or aryl) including alkylene, alkenyl or alkynyl ester (alkylene attachment to compound), carboxyester (carbonyl attachment to compound) or hydroxyester (oxygen attachment to compound), thioether (preferably, Ci-C7 alkyl or aryl), thioester (preferably, C1-C7 alkyl or aryl), amine (including a five- or six-membered cyclic alkylene amine, including an optionally substituted Ci-C6 alkyl amine (e.g., monoalkanolamine) or an optionally substituted C1-C6 dialkyl amine (e.g. dialkanolamine), alkanol (preferably, Ci-C6 alkyl or aryl), or alkanoic acid (preferably, CpC6 alkyl or aryl), optionally substituted carboxyamide (carbonyl attached to the carbon atom with one or two substituents on the amine group- preferably H or an optionally substituted Ci-C6 alkyl group), amido group (amine group with H or C1-C3 alkyl group attached to the carbon atom with a single group, preferably H or an optionally substituted C1-C6 alkyl group on the keto group) or an optionally substituted urethane group (with either the amine or the 0-carboxy group attached to a carbon atom to which the urethane is a substituent- the amine group being substituted with one or two H or one or two C1-C6 alkyl groups), -O-alkyl aryl, -O-alkenyl aryl, -O- alkynyl aryl, -O-alkyl heteroaryl, -O-alkenyl heteroaryl, and -O-alkynyl heteroaryl. Preferably, the term "substituted" shall mean within the context of its use alkyl, alkoxy, halogen, hydroxyl, carboxylic acid, cyano, ether, ester, acyl, nitro, amine (including mono- or di- alkyl substituted amines) and amide, as otherwise described above. Any substitutable position in a compound according to the present invention may be substituted in the present invention. Preferably no more than 5, more preferably no more than 3 substituents are present on a single ring or ring system. Preferably, the term "unsubstituted" shall mean substituted with one or more H atoms. It is noted that in describing a substituent, all stable permutations of the substituent are intended.
Preferred substituents for use in the present invention include, for example, F, Cl, CN, NO2, NH2, NHCH3, N(CH3)2, CH3, CH2OH, COOH, CH2CH3, CH2OCH3, CF3, COCH3, CO2CH3, CH2CO2CH3, optionally substituted naphthyl (including 1-naphthyl), thienyl, optionally substituted furanyl (especially CH2OCH2-furanyl), optionally substituted 2- or 3- pyridyl (especially CH2-pyridyl or CH2θCH2-pyridyl), optionally substituted isoquinoline (especially 4-isoquinoline), optionally substituted pyrimidyl and optionally substituted phenyl, including benzyl (CH2OCH2-phenyl).
As used herein, the term "MIF" refers to macrophage migration inhibitory factor or active fragments thereof. Accession number EMBL Z23063 describes the nucleic acid sequence encoding human MIF (Bernhagen et al., Biochemistry 33:14144-14155 (1994)). An active fragment of MIF may comprise a fragment or a portion of the MIF protein encoding the tautomerase enzymatic activity of MIF, or a fragment that is capable of binding CD74.
As used herein a "MIF agonist" refers to any agent that mimics, activates, stimulates, potentiates or increases the biological activity of MIF. A MIF agonist may be MIF or a fragment thereof; an agent that mimics MIF (such as a small molecule); an agent that increases or enhances the expression of MIF, CD74 or CD44; an agent that enhances the binding of MIF to CD74; an agent than enhances the interaction between CD74 and CD44 (including, without limitation, a bivalent agent).
As used herein, the "biological function of MIF" refers to the ability of MIF to carry out one or more of the biological functions of MIF including, without limitation, sustaining immune cell survival or activation, promoting cytokine promotion, down-regulating CCR5, binding to CD74, activating MAP kinase signaling (e.g., ERK1/2, JNK, and SAPK MAP kinase signaling), inhibiting p53, acting as a tautomerase, and/or acting as a thiol reductase.
As used herein a "MIF antagonist" refers to any agent that attenuates, inhibits, opposes, counteracts, or decreases the biological activity of MIF. A MIF antagonist may be an agent that inhibits or neutralizes MIF activity (including, without limitation, small molecules and anti-MIF antibodies); an agent that inhibits or decreases the expression of MIF (including, without limitation, an antisense molecule); an agent that inhibits or decreases the expression of the CD44 receptor (including, without limitation, an antisense molecule or an RNAi molecule); an agent that prevents the binding of MIF to CD74 (including, without limitation, an anti-CD74 antibody or an anti-MIF antibody or a fragment thereof); an agent that prevents the interaction between CD74 and CD44 (such as an anti-CD74 antibody or an anti-CD44 antibody or a fragment thereof); or an agent that prevents the interaction between CD74 and CD44. Examples of such molecules are fragments of CD74 and CD44, such as soluble fragments of such receptors. Examples of MIF antagonists have been disclosed previously, see, e.g., U.S. Patent Nos. 6,774,227, Bernhagen et al., Nature 365, 756-759 (1993), Senter et al., Proc Natl Acad Sci USA 99:144-149 (2002); Dios et al., J. Med. Chem. 45:2410-2416 (2002); Lubetsky et al., J Biol Chem 277:24976-24982 (2002), which are hereby incorporated by reference.
"Modulate levels of MIF expression" means to increase or decrease levels of MIF expression.
As used herein, the term "treating" refers to preventing, slowing, delaying, stopping or reversing the progression of a disease and/or condition.
Methods of Treating Diseases Associated with High or Low MIF Expression
In certain embodiments, the invention features methods of treating diseases associated with high or low MIF expression comprising administering to a subject in need thereof a therapeutically effective amount of a MIF agonist or a MIF antagonist. In one embodiment, the invention comprises administering to a subject having, or at risk of developing, a disease associated with high MIF expression a therapeutically effective amount of a MIF antagonist. In another embodiment, the invention comprises administering to a subject having, or at risk of developing, a disease associated with low MIF expression a therapeutically effective amount of a MIF agonist.
As described further hereinafter, diseases associated with high MIF expression include, without limitation, diseases caused by infection by a protozoan (for example malaria) fungus, bacteria and viruses, including flavivirus, such as West Nile, Dengue, Japanese encephalitis, St Louis encephalitis, or equine encepahalitis viruses; anemia of chronic disease; asthma and autism spectrum disorder (ASD). As described further hereinafter, diseases associated with low MIF expression include, without limitation, any infection and the diseases caused by infections. In one embodiment, the infection is an acute infection. In one embodiment, the infection is a bacterial infection. In another embodiment, the infection is a viral infection. In another embodiment, the infection is a fungal infection. In one embodiment, the disease associated with low MIF expression is sepsis. In another embodiment, the disease associated with low MIF expression is an infection that leads to a respiratory disease (or a respiratory disease resulting from an infection), including without limitation, infections and diseases caused by gram positive and gram negative bacteria, mycobacteria (such as mycobacterium tuberculosis), fungal infections (e.g., infections of Pneumocystis, Candida, and Histoplasma) and viral infections (e.g., infections of influenza, varicella, and corona virus such as SARS- associated coronoavirus). In another embodiment, the disease associated with low MIF expression is meningitis. In another embodiment, the disease associated with low MIF expression is influenza. In one embodiment, the disease associated with low MIF expression is pneumonia (regardless of whether it is caused by a bacterial, viral or fungal infection). In a specific embodiment, the pneumonia is Community Acquired Pneumonia (CAP). In one embodiment, the viral infection is a retroviral infection. In one embodiment, the retroviral infection is HIV infection. In another embodiment, the disease associated with low MIF expression is infection by a virus or other pathogen that use the CCR5 receptor for infection, including, without limitation, HIV-I, HCV, Epstein-Barr Virus, and Yersinia pestis.
The Use of MIF Antagonists to Treat Anemia of Chronic Disease
In one embodiment, the invention provides a method of treating anemia of chronic disease comprising administering to a subject a therapeutically effective amount of a MIF antagonist. In certain embodiment, the subject has or is at risk of developing anemia of chronic disease. In one embodiment, the subject has anemia of chronic disease and the subject is not responsive to erythropoietin (EPO) prior to the administration of the MIF antagonist. In one embodiment, the subject is has a genotype that is associated with high MIF expression. In one embodiment, the subject is Caucasian. Anemia of chronic disease may result from, among other conditions, pathogenic infection (e.g., a malaria infection), cancer, autoimmune diseases or disorders (lupus erythematosis, arthritis, including rheumatoid arthritis, kidney diseases or disorders, organ transplant rejection and aging. The invention provides a method of treating anemia of chronic disease regardless of its cause.
The methods described herein may also comprise the administration of one or more other therapeutic agents. In certain embodiments, the invention provides a method of treating anemia of chromic disease comprising administering to a subject a therapeutically effective amount of a MIF antagonist in combination with one or more other agents that stimulate erythropoiesis. Examples of erythropoiesis-stimulating agents include, without limitation: erythropoietin ("EPO"), iron, folate, vitamin B 12, blood, blood substitute, and plasma or serum that contains a composition with the activity of blood. In a specific embodiment, the invention provides a method of treating anemia of chromic disease, comprising administering to a subject in need thereof a MIF antagonist in combination with EPO.
In another embodiment, the invention provides a method of treating anemia of chronic disease, comprising administering to a subject a MIF antagonist in combination with a tumor necrosis factor-α (TNFα) antagonist or an interferon (IFN) antagonist (e.g., an IFNγ antagonist) to a subject. Examples of TNFα and IFNγ antagonists include, without limitation, anti-TNF, soluble TNF receptor, anti-IFNγ, soluble IFNγ receptor, p38 MAPK inhibitors, and JAK-STAT inhibitors.
The Use of MIF Antagonists to Malaria
The invention also comprises a method of treating malaria comprising administering to a subject in need thereof a MIF antagonist. In one embodiment, the subject has malaria or is at risk of developing malaria. In one embodiment, the subject is has a genotype that is associated with high MIF expression. In one embodiment, the subject is Caucasian.
The methods described herein may also comprise the administration of one or more other therapeutic agents.
The Use of MIF Agonists to Treat or Prevent Infections The invention also comprises a method of treating an infection comprising administering to a subject a therapeutically effective amount of a MIF agonist. In one embodiment, the subject is has a genotype that is associated with low MIF expression.
Infections and diseases that are amenable to treatment with a MIF agonist include, without limitation, viral infections (including retroviral infections), bacterial infections, fungal infections, infections leading to respiratory disease, infections with HIV, pneumonia, Community Acquired Pneumonia (CAP), meningitis, and influenza, hi certain embodiments, a MIF agonist is used to treat pathogenic infections during acute stages of infection, including during a flare-up of the infection, during a change of therapy, when signs of resistance to therapy are displayed in the subject, or as an early intervention.
In one embodiment, the invention provides a method of treating an infection that leads to a respiratory disease comprising administering to a subject a therapeutically effective amount of a MIF agonist. Infections that lead or may lead to respiratory disease include, without limitation, infections by gram positive and gram negative bacteria, mycobacteria (such as mycobacterium tuberculosis), fungal infections (e.g., infections of Pneumocystis, Candida, and Histoplasmά) and viral infections (e.g., infections of influenza, varicella, and corona virus such as SARS-associated coronoavirus).
The invention also provides a method of treating a respiratory disease resulting from an infection comprising administering to a subject a therapeutically effective amount of a MIF agonist.
In certain embodiments, the invention provides a method of treating pneumonia in a subject comprising administering to the subject a therapeutically effective amount of a MIF agonist. Microbial infections that lead to pneumonia include, without limitation, bacterial infections (e.g., infections of gram positive bacteria, gram negative bacteria, and mycobacteria such as mycobacterium tuberculosis), fungal infections (e.g., infections of Pneumocystis, Candida, and Histoplasma) and viral infections (e.g., infections of influenza, varicella, and corona virus such as SARS-associated coronoavirus). hi certain embodiments, the invention provides a method of treating a retroviral infection comprising administering to a subject a therapeutically effective amount of a MIF agonist.
In certain embodiments, the invention provides a method of treating HIV infection comprising administering to a subject a therapeutically effective amount of a MIF agonist. The invention also comprises the use of a MIF agonist as an immunoadjuvant.
The methods described herein may also comprise the administration of one or more other therapeutic agents, including without limitation anti-bacterial agents, anti-fungal agents and anti-microbial agents.
Examples of anti-viral agents include, without limitation, reverse transcriptase inhibitors such as, for example, zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, nevirapine, delavirdine, and efavirenz; protease inhibitors such as, for example, saquinavir, ritonavir, nelfinavir, indinavir, amprenavir, and lopinavir; agents for treating herpes viruses such as, for example, acyclovir, valacyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, and cidolovir; and, agents for treating influenza such as, for example, oseltamivir, amantadine, rimatadine, and zanamivir. Examples of anti-bacterial agents include, without limitation, penicillins, cephalosporins, quinolones, tetracyclines, macrolides. Examples of anti-fungal agents include, without limitation, amphotericin, fluconozole.
Methods of Using a MIF Agonist to Attenuate Expression ofCCR5 and Treat HIV Infection
In one embodiment, the invention provides a method of attenuating the expression of CCR5 mRNA or protein, comprising the use of a MIF agonist. For example, in one embodiment, cells expressing a CCR5 receptor are contacted with a MIF agonist wherein said contacting results in the attenuation of the expression of CCR5 mRNA or protein.
In another embodiment, the invention provides a method of inhibiting the life-cycle of a virus in a subject infected with said virus or at risk of being infected with said virus, wherein the virus uses the CCR5 as a receptor, administering to the subject a MIF agonist. In one embodiment, the pathogen that uses the CCR5 for infection is HIV-I .
As used herein the "inhibiting the life cycle of a virus" includes, inhibiting viral replication, inhibiting viral infection, latency and oncogenesis.
In a specific embodiment, the invention provides a method of treating HIV infection in a subject infected or at risk of being infected with HIV, comprising administering to the subject a MIF agonist. In one embodiment, the subject is has a genotype that is associated with low MIF expression. In certain embodiments, a MIF agonist is administered to a subject during acute HFV infection or during a flareup. The methods described herein may also comprise the administration of one or more other therapeutic agents. In one embodiment, the methods described herein comprise the administration of a MIF agonist in combination with anti-viral agents. Examples of anti-viral agents include, without limitation, reverse transcriptase inhibitors such as, for example, zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, nevirapine, delavirdine, and efavirenz; protease inhibitors such as, for example, saquinavir, ritonavir, nelfinavir, indinavir, amprenavir, and lopinavir; agents for treating herpes viruses such as, for example, acyclovir, valacyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, and cidolovir; and, agents for treating influenza such as, for example, oseltamivir, amantadine, rimatadine, and zanamivir.
In another aspect, the invention provides a method of treating HIV infection in a subject comprising administering to the subject a therapeutically effective amount of a MIF agonist. In one embodiment, the HIV infection is at an acute stage. In one embodiment, the method further comprises administering to the subject another anti-viral agent.
In one aspect, the invention provides a method of modulating the biological function of MIF, comprising the use of an agent that interacts modulates the interaction of CD44 with CD74.
In one embodiment, the invention provides a method of attenuating the biological function of MIF, comprising the use of an agent that inhibits the interaction between CD44 and CD74. The agent may be any agent. In one embodiment, the agent is selected from the group consisting of: a fragment of CD44, an extracellular fragment of CD44, an agent that binds CD44, an antibody or fragment thereof that binds to CD44, a small molecule, a small molecule mimic of chondroitin sulfate, heparin and a macromolecular mimic of chondroitin sulphate.
In another embodiment, the invention provides a method of attenuating the biological function of MIF, comprising the use of an agent that inhibits the expression of CD44. The agent may be any agent. In one embodiment, the agent is an siRNA or antisense polynucleotide that targets CD44.
In one embodiment, the invention provides a method of increasing the biological function of MIF, comprising the use of an agent that increases the interaction between MIF, CD44 and CD74. In one embodiment, the invention provides a method of increasing the biological function of MIF, comprising the use of an agent that increases the interaction between CD44 and CD74.
As used herein, a "disease associated with high MIF expression" or a "disease associated with low MIF expression" is a disease associated with high or low MIF expression, respectively. This association can be established using well known methods. For example, diseases that are associated with high MIF expression include: autoimmunity, cancer, anemia of chronic disease, malaria, and asthma. Diseases that are associated with low, or insufficient, MIF expression include: infections (including viral, bacterial and fungal infections) and diseases resulting from, or caused by, infections, including respiratory diseases resulting from any infection, meningitis, pneumonia, CAP, influenza, sepsis, HIV infection, and infection with a pathogen that uses CCR5 as a receptor (such as HIV-I, Hepatitis C Virus (HCV), Epstein-Barr Virus, or Yersinia pestis).
Representative cancers which may be treated using compounds according to the present invention include, for example, stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/CNS, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, leukemia, melanoma, non-melanoma skin cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, glioma, teratoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, kidney cancer and other lymphoma, among others.
Compounds according to the present invention may be administered in combination with additional anticancer agents. These agents include, for example, antimetabolites, inhibitors of topoisomerase I and II, alkylating agents and microtubule inhibitors (e.g., taxol). Specific anticancer compounds for use in the present invention include, for example, adriamycin aldesleukin; alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine; anastrozole; arsenic trioxide; Asparaginase; BCG Live; bexarotene capsules; bexarotene gel; bleomycin; busulfan intravenous; busulfan oral; calusterone; capecitabine; carboplatin; carmustine; carmustine with Polifeprosan 20 Implant; celecoxib; chlorambucil; cisplatin; cladribine; cyclophosphamide; cytarabine; cytarabine liposomal; dacarbazine; dactinomycin; actinomycin D; Darbepoetin alfa; daunorubicin liposomal; daunorubicin, daunomycin; Denileukin diftitox, dexrazoxane; docetaxel; doxorubicin; doxorubicin liposomal; Dromostanolone propionate; Elliott's B Solution; epirubicin; Epoetin alfa estramustine; etoposide phosphate; etoposide (VP- 16); exemestane; Filgrastim; floxuridine (intraarterial); fludarabine; fluorouracil (5-FU); fulvestrant; gemcitabine, gemtuzumab ozogamicin; goserelin acetate; hydroxyurea; Ibritumomab Tiuxetan; idarubicin; ifosfamide; imatinib mesylate; Interferon alfa-2a; Interferon alfa-2b; irinotecan; letrozole; leucovorin; levamisole; lomustine (CCNU); meclorethamine (nitrogen mustard); megestrol acetate; melphalan (L- PAM); mercaptopurine (6-MP); mesna; methotrexate; methoxsalen; mitomycin C; mitotane; mitoxantrone; nandrolone phenpropionate; Nofetumomab; LOddC; Oprelvekin; oxaliplatin; paclitaxel; pamidronate; pegademase; Pegaspargase; Pegfilgrastim; pentostatin; pipobroman; plicamycin; mithramycin; porfϊmer sodium; procarbazine; quinacrine; Rasburicase; Rituximab; Sargramostim; streptozocin; talbuvidine (LDT); talc; tamoxifen; temozolomide; teniposide (VM-26); testolactone; thioguanine (6-TG); thiotepa; topotecan; toremifene; Tositumomab; Trastuzumab; tretinoin (ATRA); uracil mustard; valrubicin; valtorcitabine (monoval LDC); vinblastine; vinorelbine; zoledronate; and mixtures thereof, among others.
A "disease associated with high MIF expression" or a "disease associated with low MIF expression" also includes a disease in which an endogenous MIF response to treatment causes or exacerbates the disease. For example, a "disease associated with high MIF expression" includes an inflammatory or atherosclerotic lesion or a disorder that proves resistant to steroid treatment.
As used herein, "anemia of chronic disease" refers to anemia that is immune driven. Anemia of chronic disease also known as "anemia of inflammation." This condition can result from a condition selected from the group consisting of: a pathogenic infection, cancer, an autoimmune disease or disorder, a kidney disease or disorder, organ transplant rejection, and aging. See, e.g., Weiss and Goodnought, "Anemia of Chronic Disease", N. Engl. J. Med. 352(10): 1011-23 (2005).
As used herein, the term "therapeutically effective amount" refers to the amount of a MIF agonist or antagonist (isolated or recombinantly produced), or a composition comprising a MIF agonist or antagonist, that is in sufficient quantities to treat a subject having, or at risk of developing, a disease associated with high or low MIF expression, or to treat a disease associated with high or low MIF expression itself. For example, an effective amount is sufficient to delay, slow, or prevent the onset or progression of a disease associated with high or low MIF expression, or related symptoms. The term "pharmaceutically acceptable" refers to a carrier, additive or excipient which is not unacceptably toxic to the subject to which it is administered. Pharmaceutically acceptable excipients are described at length by E. W. Martin, in "Remington's Pharmaceutical Sciences", among others well-known in the art.
A "pharmaceutically acceptable salt" of the present compound generally refers to pharmaceutically acceptable salts form of a compound which can form a salt, because of the existence of for example, amine groups, carboxylic acid groups or other groups which can be ionized in a sample acid-base reaction. A pharmaceutically acceptable salt of an amine compound, such as those contemplated in the current invention, include, for example, ammonium salts having as counterion an inorganic anion such as chloride, bromide, iodide, sulfate, sulfite, nitrate, nitrite, phosphate, and the like, or an organic anion such as acetate, malonate, pyruvate, propionate, fumarate, cinnamate, tosylate, and the like. Certain compounds according to the present invention which have carboxylic acid groups or other acidic groups which may may form pharmaceutically acceptable salts, for example, as carboxylate salts, are also contemplated by the present invention.
Aspects of the present invention include compounds which have been described in detail hereinabove or to pharmaceutical compositions which comprise an effective amount of one or more compounds according to the present invention, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
The term "pharmaceutically acceptable derivative" is used throughout the specification to describe any pharmaceutically acceptable prodrug form (such as an ester or ether or other prodrug group) which, upon administration to a patient, provides directly or indirectly the present compound or an active metabolite of the present compound.
The term "inhibitory effective concentration" or "inhibitory effective amount" is used throughout the specification to describe concentrations or amounts of compounds according to the present invention which substantially or significantly modulate levels of MIF expression.
The term "preventing effective amount" is used throughout the specification to describe concentrations or amounts of compounds according to the present invention which are prophylactically effective in preventing, reducing the likelihood of infection or delaying the onset of a disease associated with high or low levels of MIF expression. The terms inhibitory effective amount or preventive effective amount also generally fall under the rubric "effective amount".
The term "co-administration" is used to describe the administration of two active compounds, in this case a compound according to the present invention, in combination with an additional MIF-modulating agent or other biologically active agent, in effective amounts. Although the term co-administration preferably includes the administration of two active compounds to the patient at the same time, it is not necessary that the compounds actually be administered at the exact same time, only that amounts of compound will be administered to a patient or subject such that effective concentrations are found in the blood, serum or plasma, or in the pulmonary tissue at the same time.
General Information Relating to Methods of Treatment Using MIF Agonists or MIF Antagonist
The methods described herein for treating a subject suffering from or at risk of developing a disease or condition associated with high or low levels of MIF expression may be used for the prophylactic treatment of individuals who have been diagnosed or predicted to be at risk for developing a disease or condition associated with high or low MIF expression. Thus, in one embodiment, a composition comprising a MIF agonist or antagonist is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of a disease or condition associated with high or low MIF expression, or related symptoms, or to reverse a disease or condition associated with high or low MIF expression. It is understood that an effective amount of a composition for treating a subject who has been diagnosed or predicted to be at risk for developing a disease or condition associated with high or low MIF expression is a dose or amount that is in sufficient quantities to treat a subject or to treat the disorder itself.
MIF agonists and antagonists may be formulated with a pharmaceutically acceptable carrier. For example, a MIF agonist or antagonist can be administered alone or as a component of a pharmaceutical formulation (therapeutic composition). The MIF agonist or antagonist may be formulated for administration in any convenient way for use in human medicine.
In certain embodiments, the therapeutic methods of the invention include administering the composition topically, systemically, or locally. For example, therapeutic compositions of the invention may be formulated for administration by, for example, injection (e.g., intravenously, subcutaneously, or intramuscularly), inhalation or insufflation (either through the mouth or the nose) or oral, buccal, sublingual, transdermal, nasal, or parenteral administration. The compositions described herein may be formulated as part of an implant or device. When administered, the therapeutic composition for use in this invention is in a pyrogen-free, physiologically acceptable form. Further, the composition may be encapsulated or injected in a viscous form for delivery to the site where the target cells are present. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA. In addition to MIF agonists or antagonists, therapeutically useful agents may optionally be included in any of the compositions described herein. Furthermore, therapeutically useful agents may, alternatively or additionally, be administered simultaneously or sequentially with a MIF agonist or antagonist according to the methods of the invention.
In certain embodiments, compositions comprising a MIF agonist or antagonist can be administered orally, e.g., in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in- water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of an agent as an active ingredient. An agent may also be administered as a bolus, electuary or paste.
In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, and the like), one or more compositions comprising a MIF agonist or antagonist may be mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.
Suspensions, in addition to the active compounds, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
Certain compositions disclosed herein may be administered topically, either to skin or to mucosal membranes. The topical formulations may further include one or more of the wide variety of agents known to be effective as skin or stratum corneum penetration enhancers. Examples of these are 2-pyrrolidone, N-methyl-2-pyrrolidone, dimethylacetamide, dimethylformamide, propylene glycol, methyl or isopropyl alcohol, dimethyl sulfoxide, and azone. Additional agents may further be included to make the formulation cosmetically acceptable. Examples of these are fats, waxes, oils, dyes, fragrances, preservatives, stabilizers, and surface active agents. Keratolytic agents such as those known in the art may also be included. Examples are salicylic acid and sulfur.
Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required. The ointments, pastes, creams and gels may contain, in addition to a MIF agonist or antagonist, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to a MIF agonist or antagonist, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
In certain embodiments, pharmaceutical compositions suitable for parenteral administration may comprise a MIF agonist or antagonist in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
A composition comprising a MIF agonist or antagonist may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.
General Chemistry for Producing Compositions According to the Present Invention
Chemical syntheses of compounds of structure (I) above are generally prepared by cyclizing intermediates to form five or 6:5 fused heterocyclic rings. The intermediates which are initially prepared or purchased may be readily cyclized to form the various compounds according to the present invention. Various analogous chemical schemes are presented which result in the present compounds.
Benzooxazolone derivatives of the invention can be prepared as follows.
Representative procedure for 5-methyl-3H-benzooxazol-2-one derivatives 1, 5, 6 and 7
Figure imgf000034_0001
To a solution of 2-amino-4-methylphenol (1.0 gm, 8.13 mmol) and Et3N (1.6 gm, 16.26 mmol) in CH2Cl2 (20 ml) was added 4-nitrophenylchloroformate (1.8 gm, 8.94 mmol) as a CH2Cl2 solution at 0 0C for 10 min under nitrogen atmosphere and the reaction mixture was allowed to warm to rt (room temperature) and stirred for 1 h. The reaction mixture was diluted with CH2Cl2 (15 ml) and washed with water and brine. The organic phase was dried over anhydrous MgSO4 and evaporated under vacuum. The product was purified by column chromatography, eluting with n-hexane:AcOEt (2:8) on silica gel to give 5- methylbenzo[d]oxazol-2(3H)-one as an off-white solid (900 mg, 75%). To a solution of 5-methylbenzo[d]oxazol-2(3H)-one (95 mg, 0.63 mmol) and K2CO3 (342 mg, 1.89 mmol) in CH3CN (3 ml) was added 3-methoxybenzyl bromide (230 mg, 0.69 mmol) at 40 0C and the reaction was stirred under nitrogen atmosphere for 3 h. The reaction mixture was poured into ice water and extracted with AcOEt (2 X 5 ml), the combined organic layers were dried over anhydrous MgSO4 and evaporated under vacuum. The product was purified by column chromatography, eluting with n-hexane: AcOEt (1:1) on silica gel to yield 5 as a colorless solid (120 mg, 71%). Synthesis of 3-benzyl-6-methyl-3H-benzooxazol-2-one (2)
Figure imgf000034_0002
A solution of 2-amino-5-methyl-phenol (1.0 gm, 8.1 mmol) in CH2Cl2 (30 ml) was cooled to 0 0C. Triphosgene (721 mg, 2.43 mmol) was added followed by diisopropylethylamine (7.0 ml, 17.6 mmol) and the reaction mixture was stirred under nitrogen atmosphere for 2 h. The reaction mixture was washed with water and brine. The organic phase was dried over anhydrous MgSO4 and evaporated under vacuum. The crude product 6- methylbenzo[d]oxazol-2(3H)-one was used for the next step without any purification. To a solution of 6-methylbenzo[d]oxazol-2(3H)-one (300 mg, 1.98 mmol) and K2CO3 (668 mg, 4.95 mmol) in DMF was added benzyl bromide (375 mg, 2.1 mmol) at 45 0C and the reaction was stirred under nitrogen atmosphere for 5 h. The reaction mixture was poured into ice water and the precipitate was filtered, washed with n-hexane and dried under vacuum to give compound 2 (250 mg, 50%) as a white solid.
Synthesis of 5-methoxy-3-(3-methoxy-benzyl)-3H-benzooxazol-2-one (3)
Figure imgf000035_0001
To a solution of 2-amino-4-methoxy-phenol (2.46 gm, 17.7 mmol) and Et3N (5.3 gm, 53.1 mmol) in CH2Cl2 (40 ml) was added 4-nitro phenylchloroformate (3.75 gm, 19.47 mmol) as a CH2Cl2 (20 ml) solution at 0 0C for 10 min under nitrogen atmosphere and the reaction mixture was stirred to rt for 1 h. The reaction mixture was diluted with CH2Cl2 (40 ml) and washed with water and brine. The organic phase was dried over anhydrous MgSO4 and evaporated under vacuum. The product was purified by column chromatography, eluting with «-hexane: AcOEt (4:6) to give 5-methoxy-3H-benzooxazol-2-one as off white solid (2.3 gm,
0 ).
To a solution of 5-methoxy-3H-benzooxazol-2-one (150 mg, 0.90 mmol) and K2CO3 (376 mg, 2.7 mmol) in DMF (5 ml) was added 3-methoxybenzyl bromide (200 mg, 0.99 mmol) at 45 0C and the reaction mixture was stirred under nitrogen atmosphere for 3 h. The reaction mixture was poured into ice water and extracted with ethyl acetate (2 X 8 ml), the combined organic layers were dried over anhydrous MgSθ4 and evaporated under vacuum. The residue was purified by column chromatography, eluting with «-hexane: AcOEt (1 : 1) to yield 3 (181 mg, 76%) as a colorless solid.
Synthesis of 5-hvdroxymethyl-3-(3-methoxy-benzylV3H-benzooxazol-2-one (4) Ethylene glycol Toluene MeOH, H2| reflux, 12 h 83% rt, 3 h,
Figure imgf000035_0002
Figure imgf000035_0003
Figure imgf000035_0004
Figure imgf000036_0001
A mixture of 4-hydroxy-3-nitro-benzaldehyde (1.0 gm, 5.9 mmol), ethylene glycol (885 mg, 14.75 mmol) and catalytic amount of PTSA (pyridinium /?-toluenesulfonate) were refluxed in toluene (30 ml) under nitrogen atmosphere for 12 h. The reaction mixture was concentrated and poured into ice water and extracted with AcOEt (2 X 15 ml), the combined organic layers were dried over anhydrous MgSO4 and evaporated under vacuum. The reaction mixture was purified by column chromatography, eluting with n-hexane:AcOEt (1 :1) to yield 4- [l,3]dioxolan-2-yl-2-nitro-phenol (1.0 gm, 83%) as a yellow solid.
A mixture of 4-[l,3]dioxolan-2-yl-2-nitro-ρhenol (900mg, 4.26 mmol) and Pd/C (10%, 150 mg) in MeOH (15 ml) was stirred at rt under H2 pressure (30 psi) for 3 h. The reaction mixture was filtered through celite and evaporated under vacuum to obtain 2-amino-4- [l,3]dioxolan-2-yl-phenol (771 mg). This was used as such for the next step. To a solution of 2-amino-4-[l,3]dioxolan-2-yl-phenol(290 mg, 1.6 mmol) and diisopropylethylamine in CH2Cl2 (15 ml) was added triphosgene (166 mg, 0.56 mmol) as a CH2Cl2 (3 ml) solution for 5 min at 0 0C under nitrogen atmosphere and the reaction mixture was allowed to come to rt, and stirred for 2 h. The reaction mixture was washed with water and brine. The organic phase was dried over MgSO4 and evaporated under vacuum. The reaction mixture was purified by chromatography, eluting with n-hexane: AcOEt (4:6) to obtain 5-[l,3]dioxolan-2-yl-3H-benzooxazol-2-one (220 mg, 66%) as a white solid. To a solution of 5-[l,3]dioxolan-2-yl-3H-benzooxazol-2-one (100 mg, 0.48 mmol) and K2CO3 (132mg, 0.96 mmol) in DMF (5 ml) was added 3-methoxybenzyl bromide (132 mg, 0.48 mmol) at 45 0C and the reaction was stirred under nitrogen for 3 h. The reaction mixture was poured into ice water and extracted with ethyl AcOEt (2 X 5ml) the combined organic layers were dried over anhydrous MgSO4 and evaporated under vacuum. The residue was purified by column chromatography, eluting with w-hexane: AcOEt (1 :1) to yield 5- [l,3]dioxolan-2-yl-3-(3-methoxy-benzyl)-3H-benzooxazol-2-one (120 mg, 76%) as a colorless solid. To a solution of 5-[l,3]dioxolan-2-yl-3-(3-methoxy-ben2yl)-3H-benzooxazol-2-one in acetone (5 ml) was added catalytic amount of PTSA and stirred at it under nitrogen atmosphere for 1 h. The reaction mixture was diluted with ethyl acetate, to this water and brine wash was given. The organic layer was dried over anhydrous MgSO4 and evaporated under vacuum to obtain 3-(3-methoxy-benzyl)-2-oxo-2,3-dihydro-benzooxazole-5- carbaldehyde (110 mg) as a solid. This was used as it is for the next step. To a solution of 3-(3-methoxy-benzyl)-2-oxo-2,3-dihydro-benzooxazole-5-carbaldehyde (1 lOmg, 0.38 mmol) in MeOH (5 ml) was added NaBH4 (5 mg, 0.11 mmol) at ice temperature and stirred for 45 min under nitrogen atmosphere, reaction mixture was diluted with ethyl acetate (10 ml) and washed with water and brine. The organic layer was dried over MgSO4 and evaporated under vacuum. The residue was purified by column chromatography eluting with «-hexane: AcOEt (3:7) to yield compound 4 (60 mg, 56%) as colorless solid
Representative procedure for 5-fluoro-benzooxazol-2-one derivatives 8. 9. and 10
Figure imgf000037_0001
To a solution of 5-fluorobenzo[d]oxazol-2(3H)-one (100 mg, 0.65 mmol) and K2CO3 (278 mg, 1.95 mmol) in DMF (3 ml) was added 2-methoxybenzyl bromide (375 mg, 2.1 mmol) at 45 0C and the reaction was stirred under nitrogen atmosphere for 5 h. The reaction mixture was poured into ice water and the precipitate was filtered, washed with n-hexane and dried under vacuum to give compound 10 (140 mg, 79%) as a white solid. Representative procedure 5-hvdroxy-benzooxazol-2-one derivatives 11. 12 and 13
To a mixture of 5-hydroxy-3H-benzooxazol-2-one [Naoki, I.; Takeshi, S.; Etsuko, M.; Yasuo, K. J. Og. Chem. 2002, 67, 7424-7428] (lOOmg, 0.71 mmol) and imidazole (97.7 mg, 1.42 mmol) in DMF (4 ml) was added r-butyldimethylsilyl chloride (TBDMS-Cl, 161.7 mg, 1.06 mmol) at ice temperature under nitrogen atmosphere and the reaction was stirred for 6 h at rt. The reaction mixture was poured in to ice water and extracted with ethyl acetate for (3 X 5 ml), the combined organic layers were dried over anhydrous MgSO4 and evaporated under vacuum. The residue was purified by column chromatography eluting with n-hexane:AcOEt (2:8) to give 5-(ter/-butyl-dimethyl-silanyloxy)-3H-benzooxazol-2-one (120 mg, 63%) as white solid.
To a solution of 5-(ter/-butyl-dimethyl-silanyloxy)-3H-benzooxazol-2-one (195 mg, 1.4 mmol) in DMF (5 ml) was added 2-methoxybenzyl bromide (129 mg, 0.56 mmol) at 50 0C under nitrogen atmosphere and the reaction was stirred for 12 h. The reaction mixture was poured in to ice water and extracted with ethyl acetate for (3 X 5 ml), the combined organic layers were dried over anhydrous MgSO4 and evaporated under vacuum. The residue was purified by column chromatography, eluting with w-hexane: AcOEt (1:1) to give compound 12 (100 mg, 66%) as a white solid.
Representative procedure for 6-hvdroxy-benzooxazolone derivatives 14, 15 and 16
Figure imgf000038_0001
To a mixture of commercially available 6-hydroxy-3H-benzooxazol-2-one (500 mg, 3.3 mmol) and DHP (1.38 gm, 16.5 mmol) in DMF/ CH2Cl2 (10 ml) was added a catalytic amount of PPTS and the reaction was stirred for 16 h at rt. The reaction mixture was diluted with CH2Cl2 (25 ml) and washed with water and brine. The organic phase was dried over anhydrous MgSO4 and evaporated under vacuum. The product was purified by column chromatography, eluting with «-hexane:AcOEt (7:3) to give 6-(tetrahydro-2H-pyran-2- yloxy)benzo[d]oxazol-2(3H)-one (300 mg, 1.25 mmol, 38%) as colorless solid. To a solution of 6-(tetrahydro-2H-pyran-2-yloxy)benzo[d]oxazol-2(3H)-one (120 mg, 0.51 mmol) and K2CO3 (211 mg, 1.5 mmol) in DMF (3 ml) was added benzyl bromide (86 mg, 0.50 mmol) at 45 0C and the reaction was stirred under nitrogen atmosphere for 6 h. The reaction mixture was poured into ice water and extracted with AcOEt (3 X 5 ml) the combined organic layers were dried over anhydrous MgSO4 and evaporated under vacuum. The residue was purified by column chromatography, eluting with n-hexane: AcOEt (1 :1) on silica gel to yield 3-(benzyl)-6-(tetrahydro-2H-pyran-2-yloxy)benzo[d]oxazol-2(3H)-one (140 mg, 85%) as a colorless solid.
To a solution of 3-(benzyl)-6-(tetrahydro-2H-pyran-2-yloxy)benzo[d]oxazol-2(3H)-one (140 mg, 0.43 mmol) in MeOH (5 ml) was added catalytic amount of PPTS and the reaction was stirred for 5 h at 60 0C. The reaction mixture was diluted with CH2Cl2 (10 ml) and washed with water and brine. The organic phase was dried over MgSO4 and evaporated under vacuum. The product was purified by column chromatography, eluting with w-hexane:AcOEt (2:8) to give compound 14 (73.3 mg, 82%) as white solid.
Synthesis of 4-(l -benzyl- lH-benzordlimidazol-2-yl)thiazole (17)
Figure imgf000039_0001
To solution of commercially available thiabendazole (100 mg, 0.49 mmol) and K2CO3 (132 mg, 0.98 mmol) in DMF was added benzyl bromide (92.7 mg, 0.53 mmol) at 60 0C and the reaction was stirred under nitrogen atmosphere for 12 h. The reaction mixture was poured into ice water and extracted with AcOEt (3 X 5 ml), the combined organic layers were dried over MgSO4 and evaporated under vacuum. The residue was purified by column chromatography to yield 17 (135 mg, 0.46 mmol, 94%) as a colorless solid.
Synthesis of 1 -Benzyl- lH-benzoimidazole-2-carbonitrile (18)
Figure imgf000039_0002
Figure imgf000039_0003
Methyl 2,2,2-trichloroacetamide (1.83 gm, 17 mmol) was added to a solution of o- phenylenediamine (3 gm, 17.0 mmol) in acetic acid, which was then stirred at room temperature for 1 h. Water was added (20 mL) to the mixture, and resultant precipitate was filtered. The filtrate was washed with water and dried under vacuum to afford 2- Trichloromethyl-lH-benzoimidazole (3.4 gm, 14.4 mmol, 85%) as a dark yellow color solid.
2-trichloromethylbenzamidazole (500 mg, 2.1 mmol) was added proportion wise to anhydrous ammonia at -78 0C. The mixture was stirred 5 min at -78 0C and the cooling bath was removed. The reaction mixture was allowed to warm to room temperature. After the ammonia had evaporated the solid was extracted with boiling ethyl acetate. The organic layer was dried over MgSO4 and concentrated under vacuum. The residue was purified by column chromatography to yield lH-Benzoimidazole-2-carbonitrile (267 mg, 1.86 mmol, 88%) as a white solid.
To solution of lH-Benzoimidazole-2-carbonitrile (70 mg, 0.48 mmol) and K2CO3 (132 mg, 0.96 mmol) in DMF was added benzyl bromide (82 mg, 0.48 mmol) at 60 0C and the reaction was stirred at rt under nitrogen atmosphere for 12 h. The reaction mixture was poured into ice water and extracted with ethyl acetate for 3 times, the combined organic layers were dried over MgSO4 and evaporated under vacuum. The residue was purified by column chromatography to yield 34 (100 mg, 0.42 mmol, 89%) as a colorless solid.
Representative procedure for bisbenzofuran-2-yl methanone (20) derivatives
Chloroacetone Pyridinium tribromide K2CO3, CH3CN t acetic acid
900C, 5 h, 39% 600C, 4 h, 25%
Figure imgf000040_0003
Figure imgf000040_0002
Figure imgf000040_0001
Figure imgf000040_0004
To a solution of 2-hydroxybenzaldehyde (0.96 ml, 10 mmol) and K2CO3 (1.382 g, 10 mmol) in CH3CN (20 ml) was added chloroacetone (0.876 ml, 11 mmol) dropwise, via syringe, at room temperature. The reaction flask then was fitted with a reflux condenser and the solution was heated to 90 0C. The reaction was stirred at reflux, under nitrogen atmosphere, for 5 h. The reaction then was allowed to cool to room temperature and the reaction mixture was diluted with CH2Cl2 (20 ml). The solid salts were filtered off and the filtrate reduced under vacuum. The product was purified by column chromatography, eluting with n - hexane: AcOEt (9:1). Further purification by recrystallization from EtOH yielded 1- (benzofuran-2-yl)ethanone (630.5 mg, 39%) as a white solid.
To a solution of l-(benzofuran-2-yl)ethanone (448 mg, 2.8 mmol) in acetic acid (10 ml) was added pyridinium tribromide (1.12 g, 3.5 mmol) in portions. The reaction was warmed to 60 0C and the reaction was stirred under nitrogen atmosphere for 4 h. The reaction was then quenched with H2O (20 ml) and neutralized with saturated NaHCO3 solution. The product was extracted with AcOEt and washed with water and brine. The organic phase was dried over MgSO4 and evaporated under vacuum. The product was purified recyrstallization from EtOH to give l-(benzofuran-2-yl)-2-bromoethanone (170 mg, 25%) as a white solid. To a solution of 2,5-dihydroxybenzaldehyde (86 mg, 0.62 mmol)and K2CO3 (85 mg, 0.62 mmol) in CH3CN (5 ml) was added l-(benzofuran-2-yl)-2-bromoethanone (60 μl, 0.62 mmol) in portions. The reaction flask was then fitted with a reflux condenser and the solution was heated to 90 0C. The reaction was stirred at reflux, under nitrogen atmosphere, for 18 h. The reaction was allowed to cool to room temperature and the reaction mixture was diluted with CH2Cl2 (20 ml). The solid salts were filtered off and the filtrate reduced under vacuum. The product was purified by column chromatography, eluting with n - hexane: AcOEt (9:1). Further purification by recrystallization from EtOH yielded benzofuran- 2-yl(5-hydroxybenzofuran-2-yl)methanone (135 mg, 78%) as a white solid.
The aforementioned reactions schemes are illustrative, and those of ordinary skill in the art are aware of and may readily utilize alternative processes well known in the art for making the compounds according to the present invention described above.
Compound Characterization
The identity of all assayed compounds was confirmed by 1H-NMR, 13C-NMR, and high-resolution mass spectrometry (HRMS), and elemental analysis. The purity of all samples was demonstrated by high performance liquid chromatography. Examples of NMR spectra and HRMS data are given below and in Figures 4 and 5 for compounds 10 and 14. 1HNMR (500 MHz, CDCl3), δ 7.32-7.26 (m, 2H), 7.10-7.08 (m, IH), 6.95 (m, 2H), 6.77-6. 73 (m, 2H), 5.0 (s, 2H), 3.89 (s, 3H); 13CNMR (125 MHz, CDCl3), δ 160.44, 158.52, 157.24, 155.23, 138.66, 138.64, 130.06, 130.02, 122.50, 121.03, 110.72, 110.38,
Figure imgf000042_0001
110.30, 108.56, 108.36, 98.18, 97.94, 55.50, 41.38 HRMS (ESI-TOF) calcd for C15Hi2FNO3
[M+H]+ 274.0873, found 274.0873.
1HNMR (500 MHz, CDCl3), δ 7.33-7.28 (m, 5H), 6.78 (dd,y = 8.5, 3 Hz, IH), 6.73 (d,j = IHz, IH), 6.58-6.56 (m, IH); 13CNMR (125 MHz, MeOH-Ci4), δ 156.89, 155.26, 144.67, 136.78, 129.91,
Figure imgf000042_0002
129.12, 128.63, 124.50, 111.60, 110.72, 99.33, 46.67. HRMS (ESI-
TOF) calcd for Ci4H11NO3 [M+H]+ 242.0811, found 242.0811.
1HNMR (500 MHz, CDCl3), δ 8.65 (d,y = 2 Hz, IH), 8.35 (m, j IH), 7.60 (d, j = 8 Hz, IH), 7.10-6.92 (m, 8H), 5.86 (s, 2H); 13CNMR (125 MHz, CDCl3), δ 153.06, 148, 147.05, 143.19, 137.20, 136.11, 129.06, 128.78, 127.61, 126.83, 123.39, , 122.94, 121.44, 119.90, 110.76, 48.67; MS (m/z): ( M+l) = 291.87 (100%)
1HNMR (500 MHz, CDCl3), δ 7.80 (d,j - 7 Hz, IH), 7.35 (m, 6H), 7.18 (m, 2H), 5.50 (s, 2H); 13CNMR (125 MHz, CDCl3), δ 142.96, 134.32, 134.24, 129.38, 128.92, 127.30, 126.87, 126.68, 124.68, 121.99, 111.38, 111.0, 49.29; MS (m/z): (M+l) - 300.0 (100%).
Figure imgf000042_0003
Representative procedure for Compound 098 Table 1
Figure imgf000043_0001
Compound 098 Table 1
To a solution of 5 (7.42 g, 27.6 mmol) in DCM (500 ml) was added BBr3 (138 mL, 138 mmol) at -78 0C as IM DCM solution and stirred to rt for 2 hr. The reaction was quenched with aq.NaHCO3 followed by dilution with DCM, to this water and brine wash was given and concentrated. The crude residue was purified by column chromatography, eluting with Hexanes:AcOEt (4:1) on silica gel to give 98 (098 of Table 1) as a white solid (2.00 g, 71%). 1HNMR (400 MHz, MeOH-Cl4), δ 6.94 (t, j = 7.6 Hz, IH), 6.80 (d, j = 8.4 Hz, IH), 6.63-6.56 (m, 3H), 6.55 (d, j = 8.4 Hz, IH), 5.85 (s, IH), 4.65 (s, 2H), 2.06 (s, 3H); 13CNMR (125 MHz, CDCl3), δ 156.66, 155.56, 140.82, 136.54, 134.16, 130.85, 130.31, 123.29, 119.78, 115.62, 114.54, 109.83, 109.67, 45.95, 21.63
The invention is described further in the following description of biological assays and examples, which are illustrative and are not limiting.
Biological Assays
Two principal assays have been performed, one for inhibition of MIF tautomerase activity and the other for MIF-CD74 binding. The tautomerase assay monitored the keto/enol interconversion for /7-hydroxyphenylpyruvate (HPP) catalyzed by MIF (Stamps, S. L., (2000), Mechanism of the Phenylpyruvate Tautomerase Activity of Macrophage Migration Inhibitory Factor: Properties of the PlG, Pl A, Y95F, and N97A Mutants Biochemistry 39, 9671-9678). The related procedure used dopachrome as the substrate, as has been used previously to identify MIF inhibitors including ISO-I (Lubetsky, J. B. (2002), The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277, 24976-24982). However, it is noted that a compound may appear active in one tautomerase assay and not in the other; in fact, ISO-I is inactive in the HPP tautomerase assay. The biologically more significant assay is a "capture" assay using immobilized, recombinant MIF receptor ectodomain and biotinylated recombinant MIF (Leng, L., et al. (2003), MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467-1476). This allows measurement of the inhibition or enhancement of the binding of MIF to its receptor induced by an addend.
Two additional assays were performed on compounds according to the present invention. In the first, MIF-dependent signal transduction in cells as evidenced by a reduction in ERK1/2 phosphorylation and its inhibitory action is compared to the known small molecule MIF antagonist, isoxazoline-1 following the assay reported in Leng L., Metz C, Fang Y, Xu J, Donnelly S, Baugh J, Delonery T, Chen Y, Mitchell RA, and Bucala R. 2003. MIF Signal Transduction Initiated by Binding to CD74. J Exp Med 197, 1467-1476. One particular compound, compound 098 of Table 1, showed significant inhibitory action in this assay.
In the second additional assay, compounds of the present invention were tested to determine whether the compound inhibits the growth of an ovarian cancer cell line, following the assay reported in Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB. 2009. KSP inhibitor ARRY-520 is used as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med. 7:63. One particular compound, compound 098 of Table 1, showed significant inhibitory action in this ovarian cancer assay.
Sample Activity Data
Assay results are provided in Table 1, below for sixteen compounds in the N-benzyl- benzooxazolone series B of the invention. Strikingly potent compounds have been found for both inhibition of MIF-CD74 binding and MIF tautomerase activity. Table 1 also notes that ISO-I is inactive in the capture assay, while a biologically-neutralizing anti-MIF antibody is a 0.4 μM inhibitor. As noted previously (Senter, P. D., et al. (2002), Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Nat. Acad. Sci. USA 99, 144-9 (" Senter 2002")), a compound may be potent in one assay and relatively inactive in the other, e.g., compound 15, while some are potent in both, e.g., compound 1.
Table 1 also notes that ISO-I is inactive in the capture assay, while a biologically neutralizing anti-MIF antibody is a 0.4 μM inhibitor. Another reference compound, 4-iodo-6- phenylpyrimidine (4-IPP), also is inactive in the capture assay, but is a 4.5-μM inhibitor in the HPP tautomerase assay. 4-IPP has recently been licensed by Advanced Cancer Therapeutics from the University of Louisville; the press release notes that "4-IPP, a novel small molecule compound, exhibits anti-tumor activity by blocking tumor-specific angiogenesis, and thus far has demonstrated a favorable safety profile in laboratory studies.
As a macrophage migration inhibitory factor (MIF), this chemokine promotes multiple pro-angiogenic growth factors (VEGF and IL-8) and contributes to tumor cell division, metastases and tumor vascularization (i.e., angiogenesis). The University of Louisville researchers have shown in the laboratory that 4-IPP could serve as front-line therapy against bulk tumors and reduce the risk of recurrence of primary tumors or eventual metastasis. In addition, while initially targeted for development in oncology, 4-IPP has subsequently been evaluated for its potential to address various unmet medical needs in autoimmune related diseases such as Rheumatoid Arthritis, Lupus and Multiple Sclerosis." We view 4-IPP as an unattractive drug candidate owing to anticipated off-target activities associated with the highly electrophilic 4-iodo-pyrimidine subunit.
Figure imgf000045_0001
Table 1. Assay Results for Inhibition of M I F-C D 74 Binding and MIF Tautomerase Activity (HPP) by Benzooxazolones of structure B, above (Z4 = Z5 = H) in μM.
MIF-CD74 HPP HPP
Cmpd Ri R2 Z1 Z2 Z3 IC50 IC50 Max.
Inhib.
1 CH3 H H H H 1.5 0.5
2 H CH3 H H H 3.4
3 OCH3 H H OCH3 H 200 41%
4 CH2OH H H OCH3 H 500 44%
5 CH3 H H OCH3 H 300 2.9
6 CH3 H OCH3 H H 0.09 35%
7 CH3 H OCH3 OCH3 H 7.0 32%
8 F H H H H 25 1.0
9 F H H H OCH3 >1000 35%
10 F H OCH3 H H 17%
11 OH H H OCH3 H 30 26
12 OH H OCH3 H H >1000 30
13 OH H OCH3 OCH3 H 300 2.1 14 H OH H H H >1000 28%
15 H OH H H OCH3 3.0 23%
16 H OH OCH3 H H 15%
098 CH3 H H OH H 0.01
ISO-I > 10000 > 10000
4-IPP >10000 4.5 anti-MIF 0.4
Figure imgf000046_0001
Additional data are provided in Table 2 for illustrative active compounds in multiple other series discussed above; the specific structures are illustrated below. It is noted that for some compounds including compound 25 we observe agonist behavior, i.e., an enhancement of MIF-CD74 binding upon addition of the compound.
Table 2. Assay Results for Inhibition of M IF-CD74 Binding and MIF Tautomerase Activity (HPP) in μM.
MIF-CD74 HPP HPP
Cmpd IC50 IC50 Max.
Inhib.
17 40%
18 36%
19 38%
20 510
21 4.0 3.0
22 2.5
23 1500
24 5000
25 agonist 4.2
Figure imgf000046_0002
Table 3. Assay Results for In48hibition of MI F- C D 74 Binding and MIF Tautomerase Activity (HPP) by Benzothiazolones B (Z4 = Z5 = H) in μM.
HPP Capture Capture Cmpd Ri R2 Zx Z2 Z3 IC50 % Max. IC50 Inhib.
26 F H H H Cl 4.2 agonist
27 F H H H OCH3 6.2 NA
28 F H H OCH3 H 25 NA
29 F H H CH2OH H 4.8 8
30 H F H H Cl 2.8 7
31 H Cl OCH3 H H 6.6 7
32 H F H OH H 5.9 13
33 F H H CH2OAc H 2.3 12
34 H NO2 H H Cl 6.2 11
35 H CF3 H H Cl 8.5 12
36 Br H H H Cl 11 10
37 CN H H H Cl 3.1 16
38 H F H OCH3 H 8 agonist
39 H Br H H Cl 7.9 NA
40 H CN H H Cl 19 aeonist
Further details and descriptions of the assays used to generate the data in Tables 1, 2 and 3 are presented below.
Example 1
MIF-CD74 Binding Assay Materials and Methods
Coat 96 well plates with 60μl/well of 26 ng/ μl purified, recombinant human MIF receptor (CD74 ectodomain or CD7473"232). Incubate at 4°C overnight. Wash the plate 4 times with 250 μl/well TTBS and add 100 μl/well of superblock (Pierce, IL). Incubate at 4°C overnight. Remove the superblock and add mixture of compound and biotin-labeled recombinant human MIF incubated at 4°C overnight. (Each compound was pre-incubated at various concentrations with 2 ng/ μl 0.2 μM biotin-MIF for 2 hours at room temperature in the dark). After washing the plate 4 times with 250 μl/well TTBS, 60 μl/well of Strepavidin- AP (R&D Systems) was added and incubated for 1 hr at room temperature in the dark. Wells were then washed as before and 60 μl/well of PNPP (Sigma) was added, allowing the color to develop in the dark at room temperature and then read at OD4O5 nm.
Example 2
Inhibition of MIF Tautomerase Activity Materials and Methods The "capture" assay used immobilized, recombinant MIF receptor ectodomain and biotinylated recombinant MIF in accordance with Leng, L., et al. (2003), MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467-1476.
HPP Tautomerase Assay Materials and Methods
The HPP assay used was adapted to the microtiter plate format. Human MIF protein was purified according to Bernhagen et al. Biochemistry, 33:14144-14155, 1994. Dilutions of the enzyme were prepared in 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.5. HPP was obtained from Aldrich. A stock solution of 60 mM HPP in ethanol is prepared and kept for maximally 4 hours on ice. The working solution (600 μM) of the substrate was prepared by diluting an aliquot of the stock solution with 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.5. UV-transparent microtiter plates (96- well) were obtained from Corning (Cat#3635). Inhibitor and enzyme solutions were pipetted manually using an Eppendorf 12- channel pipette. Addition of substrate to start the reaction was performed with an Igel 96 pipetting station (OpaUena, Jena, Germany), which allows simultaneous addition of fluid to all 96 wells of the plates. Optical density (OD) was determined using a SPECTRAmax 250 reader (Molecular Devices). The reader was operated with the SoftmaxPro 2.6.1 software. Assay: Three wells of the microtiter plates were filled with buffer only, to allow for blanking. Into the test wells were pipetted consecutively: 50 μl inhibitor dilution (or buffer for control), 50 μl enzyme dilution (55 nM; final concentration in assay: 18.3 nM), 50 μ.l freshly diluted substrate working solution (600 μ.M; final concentration: 200 μ.M). The last step was performed using the 96-channel pipetting device. The plate was then immediately (i.e. within a few seconds) transferred manually to the SPECTRAmax 250 reader and the optical density was determined (310 nm). From the data obtained, IC50 values were calculated using Excel® and XLfit® software.
Figure imgf000048_0001
CD74
%max QP
R1 inhib. MW QPIogPo/w QPIogS QPPCaco #metabol
058 4-thiazole 28 291.37 4.316 -4.646 4756.675 2
060 (2-pyridinyl)methyl 40 299.374 4.905 -5.168 4899.167 3 061 nitrile 20 233.272 2.854 -4.223 1270.596 1
062 amide 25 251.287 2.214 -3.287 666.488 2
N1N-
063 dimethylamide 27 279.341 3.43 -3.907 3697.895 1
065 N-methylamide 16 265.314 3.003 -3.823 1539.521 1
066 CH3OCH2CH2 25
Additional Compounds
Compound 67
Compound 68
Compound 69
Compound 70
Figure imgf000049_0001
MIF: 19
Compound 71
Figure imgf000049_0002
%Bound IC50 MW QPIogPo/w QPIogS QPPCaco #metabol
Compound 71 1500 296.279 2.705 -3.687 78.455
Compound 72
Figure imgf000050_0001
%Bound 1C50 MW QPIogPo/w QPIogS QPPCaco #m eta bo I
Compound 72 na 288.348 3.901 -4.352 2101.693
Compound 73
Figure imgf000050_0002
HPP %Bound IC50 MW QPIogPo/w QPIogS QPPCaco #metabol IC50
Compound
73 4 263.295 3.325 -3.755 3998.157
The terms and expressions that have been employed in this application are used as terms of description and not of limitation, and there is no intent in the use of such terms and expressions to exclude any equivalent of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention as claimed. Thus, it will be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.
The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
References
Cheng, K. F. & Al-Abed, Y. (2006) Critical modifications of the ISO-I scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg. Med. Chem. Lett. 16, 3376-3379.
Jorgensen, W. L. (2004) The Many Roles of Computation in Drug Discovery. Science 303, 1813-1818.
Leng, L.; Metz, C; Fang, Y.; Xu, J.; Donnelly, S.; Baugh, J.; Delonery, T.; Chen, Y.; Mitchell, R. A. & Bucala, R. (2003) MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467-1476.
Lolis, E. & Bucala, R. (1996) Crystal structure of macrophage migration inhibitory factor (MIF), a glucocorticoid-induced regulator of cytokine production, reveals a unique architecture. Proc. Assoc. Amer. Physicians 108, 415-9.
Lolis, E. & Bucala, R. (2003) Macrophage migration inhibitory factor. Expert Opin. Therap. Targets 7, 153-164.
Lubetsky, J. B.; Swope, M.; Dealwis, C; Blake, P. & Lolis, E. (1999) Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. Biochemistry 38, 7346-54.
Lubetsky, J. B.; Dios, A.; Han, J.; Aljabari, B.; Ruzsicska, B.; Mitchell, R.; Lolis, E. & Al Abed, Y. (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277, 24976- 24982.
Morand, E.- F.; Leech, M. & Bernhagen, J. (2006) MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nature Rev. Drug Disc. 5, 399-411. Orita, M.; Yamamoto, S.; Katayama, N.; Aoki, M.; Kazuhisa, T.; Yamagiwa, Y.; Seki, N.; Suzuki, H.; Kurihara, H.; Sakashita, H.; Takeuchi, M.; Fujita, S.; Yamada, T. & Tanaka, A. (2001). Coumarin and Chromen-4-one Analogues as Tautomerase Inhibitors of Macrophage Migration Inhibitory Factor: Discovery and X-ray Crystallography. J. Med. Chem. 44, 540- 547.
Orita, M.; Yamamoto, S.; Katayama, N. & Fujita, S. (2002) Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors. Curr. Pharm. Res. 8, 1297-1317.
Pirrung, M. C; Chen, J.; Rowley, E. G. & McPhail, A.T. (1993) Mechanistic and stereochemical study of phenylpyruvate tautomerase. J. Am. Chem. Soc. 115, 7103-10.
Rosengren, E.; Bucala, R.; Aman, P.; Jacobsson, L.; Odh, G.; Metz, C. N. & Rorsman, H. (1996) The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Molec. Med. 2, 143-149.
Rosengren, E.; Aman, P.; Thelin, S.; Hansson, C; Ahlfors, S.; Bjork, P.; Jacobsson, L. & Rorsman, H. (1997) The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett. 417, 85-8.
Senter, P. D.; Al-Abed, Y.; Metz, C. N.; Benigni, F.; Mitchell, R. A.; Chesney, J.; Han, J.; Gartner, C. G.; Nelson, S. D.; Todaro, G. J.& Bucala, R. (2002) Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Nat. Acad. Sci. USA 99, 144-9.
Stamps, S. L.; Taylor, A. B.; Wang, S. C; Hackert, M. L. & Whitman, C. P. (2000) Mechanism of the Phenylpyruvate Tautomerase Activity of Macrophage Migration Inhibitory Factor: Properties of the PlG, PlA, Y95F, and N97A Mutants Biochemistry 39, 9671-9678.
Sun, H. W.; Bernhagen, J.; Bucala, R. & Lolis, E. (1996) Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc. Nat. Acad. Sci. USA 93, 5191-5196. Zhang, X. & Bucala, R. (1999) Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs. Bioorg. Med. Chem. Lett. 9, 3193-3198.

Claims

Claims:
1. A compound according to the chemical structure (I):
Figure imgf000054_0001
where X is O, N-R™1 or CRXC1RXC2;
Y is O, N-R™1 or CRYC1RYC2; and
Z is O, N-R2*1 or CRZC1RZC2, with the proviso that at least one of X or Z is N-R™1 and X and
Z are other than O, when Y is O;
R^1 is absent (N is -N=, thus forming a double bond with an adjacent atom), H or an optionally substituted Ci-Cs alkyl, alkene or alkyne group, an optionally substituted Ci-C7 acyl group, an optionally substituted (CH2)J -phenyl group or an optionally substituted
(Ctym-heterocyclic (preferably heteroaryl) group;
RYN1 is absent, H, an optionally substituted C1-C8 alkyl, alkene or alkyne group, an optionally substituted CpCg acyl group, an optionally substituted (CH2)J -phenyl group or an optionally substituted (CH2)m-heterocyclic (preferably heteroaryl) group;
R™1 is absent, H, an optionally substituted C1-C8 alkyl, alkene or alkyne group, an optionally substituted C1-Cg acyl group, an optionally substituted (CH2)J -phenyl group or an optionally substituted (CH2)m-heterocyclic (preferably heteroaryl) group;
RXC1 is absent (C is -C=, thus forming a double bond with an adjacent atom), H, an optionally substituted CpC3 alkyl, or together with RXC2 forms a =0 (keto) or =C group,
(preferably RXC1 is absent);
R is H, an optionally substituted Ci-Cg alkyl, alkene or alkyne group (preferably R is an optionally substituted C1-C3 group when RXC1 is an optionally substituted Ci-C3 group), an optionally substituted Ci-Cg acyl group, an optionally substituted C2-C8 ester or carboxyester group, an optionally substituted Ci-C7 alkoxy group, an optionally substituted C2-Cg ether group, an optionally substituted Ci-C7 amido or carboxamido group, a Ci-C7 urethane or urea group, an optionally substituted (CH2)J -phenyl group or an optionally substituted (CH2)m- heterocyclic (preferably heteroaryl) group, or together with RXC1 forms a =0 (keto) group or
=C group, which is optionally substituted with a Ci-C6 alkyl group, an optionally substituted (CH2)J -phenyl group or an optionally substituted (CH2)m-heterocyclic (preferably heteroaryl) group;
RYC1 is absent, H, an optionally substituted C1-C3 alkyl, or together with RYC2 forms a =0
(keto) group or a =C group, (preferably RYC1 is absent);
R is H, an optionally substituted Ci-Cg alkyl, alkene or alkyne group (preferably R is an optionally substituted C1-C3 group when RYC1 is an optionally substituted C1-C3 group), an optionally substituted Ci-Cg acyl group, an optionally substituted C2-Cg ester or carboxyester group, an optionally substituted Ci-C7 alkoxy group, an optionally substituted C2-Cs ether group, an optionally substituted Ci-C7 amido or carboxamido group, a Ci-C7 urethane or urea group, an optionally substituted (CH2)J -phenyl group or an optionally substituted (CH2)m- heterocyclic (preferably heteroaryl) group, or together with RYC1 forms a =0 (keto) or =C group, which is optionally substituted with a Ci-C6 alkyl group, an optionally substituted
(CH2)J -phenyl group or an optionally substituted (CH2)m-heterocyclic (preferably heteroaryl) group;
RZC1 is absent, H, an optionally substituted Cj-C3 alkyl, or together with RZC2 forms a =0
(keto) group or =C, (preferably RZC1 is absent);
RZC2 is H, an optionally substituted Ci-Cg alkyl, alkene or alkyne group (preferably RZC2 is an optionally substituted C1-C3 group when RZC1 is an optionally substituted C1-C3 group), an optionally substituted Ci-Cg acyl group, an optionally substituted C2-Cg ester or carboxyester group, an optionally substituted Ci-C7 alkoxy group, an optionally substituted C2-Cg ether group, an optionally substituted C1-C7 amido or carboxamido group, a Ci-C7 urethane or urea group, an optionally substituted (CH2)J -phenyl group or an optionally substituted (CH2)m- heterocyclic (preferably heteroaryl) group, or together with RZC1 forms a =0 (keto) group or
=C group, which is optionally substituted with a Ci-C6 alkyl group, an optionally substituted
(CH2)J -phenyl group or an optionally substituted (CH2)m-heterocyclic (preferably heteroaryl) group;
RA and RB together form an optionally substituted 5, 6 or 7 membered carbocyclic or heterocyclic ring (preferably an optionally substituted aromatic or heteroaromatic ring, more preferably an optionally substituted phenyl ring or a heteroaromatic ring containing one nitrogen group, preferably a pyridyl group); eachj is independently 0, 1, 2, 3, 4 or 5; and each m is independently 0, 1, 2, 3, 4, or 5 or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
2. The compound according to claim 1 wherein X is O, Y is CRYC1RYC2, Z is N-R™1, and RA and RB form an optionally substituted phenyl or pyridyl ring.
3. The compound according to claim 1 wherein where X is CRXC1RXC2, Y is CRYC1RYC2, Z is N-R21*11, and RA and RB form an optionally substituted phenyl or pyridyl ring.
4. The compound according to claim 1 wherein where X is N-R™1, Y is CRYC1RYC2, Z is N- R™1, and RA and RB form an optionally substituted phenyl or pyridyl ring.
5. The compound according to claim 2 wherein RYC1and RYC2 together forms a =O (keto) group and RA and RB form an optionally substituted phenyl or pyridyl ring.
6. The compound according to claim 5 wherein RZN1 is an optionally substituted (CH2)J- phenyl group.
7. The compound according to claim 1 wherein R is absent, R is an optionally substituted (CH2)J -heterocyclic group, and RA and RB form a phenyl group which is substituted by -O-alkyl aryl.
8. The compound according to claim 3 wherein R is H, R is absent, R is an optionally substituted (CH2)J -heterocyclic group, an optionally substituted C1-C7 amido group, or an optionally substituted Ci-C7 alkoxy group, and R™1 is an optionally substituted (CH2)J -phenyl group.
9. The compound according to claim 3 wherein R is selected from the group consisting of 4-thiazole, (2-pyridinyl)methyl, nitrile, amide, N,N-dimethylamide, N-methylamide and CH3OCH2CH2.
10. The compound according to claim 9 wherein R is absent and R is selected from the group consisting of 4-thiazole, (2-pyridinyl)methyl, nitrile, amide, N,N-dimethylamide, N- methylamide and CH3OCH2CH2.
11. The compound according to claim 10 wherein RA and RB form an optionally substituted phenyl group.
12. The compound according to claim 10 wherein said phenyl group is substituted with H, CH3, CH2CH3, NH2, NHCH3, N(CH3)2, OH, OCH3, SH, SCH3, F, Cl, Br or I.
13. A compound according to the chemical structure II:
Figure imgf000057_0001
Wherein X, Y and Z are as described above for compound (I); and
Ri and R2 are each independently H, OH, COOH, halogen, CN, OH, optionally substituted Ci-C8 alkyl, optionally substituted O-(Ci-C6)alkyl, SH, S-(C1-C6)alkyl, optionally substituted Ci-C8 acyl, optionally substituted C2-C8 ether, optionally substituted C2-C8 ester or carboxyester, optionally substituted C2-C8 thioester, amide optionally subsituted with a C1-C6 alkyl group, carboxyamide optionally substituted with one or two Ci-C6 alkyl or alkanol groups, and amine optionally substituted with one or two Ci-C6 alkyl or alkanol groups, or a pharmaceutically acceptable salt, enantiomer, solvate of polymorph thereof.
14. The compound according to claim 13 wherein R1 and R2 are each independently H, CH3, CH2CH3, NH2, NHCH3, N(CH3)2, OH, OCH3, SH, SCH3, F, Cl, Br or I.
15. The compound according to claim 13 wherein one of Ri and R2 is H and the other is hydroxyl, Ci-C8 alkyl, or alkoxy, and wherein Z is N-benzyl wherein said benzyl group is substituted with up to three Ci-C6 alkyl or alkoxy groups.
16. A compound according to the chemical structure:
Figure imgf000058_0001
wherein RA1 and RB1 form a 5, 6 or 7 membered optionally substituted carbocyclic (preferably a phenyl) ring or heterocyclic (preferably, heteroaryl, including a pyridyl) group;
R is H, an optionally substituted Ci-C8 alkyl, alkene or alkyne group, an optionally substituted Cs-C14 (CH2)j-carbocyclic group, or an optionally substituted C4-Ci3 (CH2)m- heterocyclic group; each j is independently 0, 1, 2, 3, 4 or 5; and each m is independently 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
17. The compound according to claim 16 wherein R6 is an optionally substituted C5-Cn (CH2)j-carbocyclic group, and RA1 and RB1 form an optionally substituted phenyl or pyridyl ring.
18. The compound according to claim 16, wherein R6 is an optionally substituted (CH2)j-aryl group.
19. The compound according to claim 16 wherein R6 is an optionally substituted (CH2)j- phenyl group or an optionally substituted (CH2)m-heteroaryl group.
20. The compound according to claim 16 wherein R6 is an optionally substituted (CH2)j- phenyl group and RA1 and RB1 together form an optionally substituted phenyl group or an optionally substituted heteroaryl group.
21. The compound according to claim 20 wherein j is 0 or 1.
22. The compound according to claim 21 wherein j and m are 0 and wherein said optionally substituted phenyl group is substituted with at least one halogen, C]-C6 alkyl or Ci-C6 alkoxy group.
23. The compound according to claim 16 wherein R6 is an optionally substituted (CH2)j-aryl group and RA1 and RB1 form an optionally substituted heteroaryl group.
24. The compound according to claim 24 wherein R6 is an optionally substituted (CH2)m- heteroaryl group and RAI and RB1 form an optionally substituted aryl group.
25. The compound according to claim 23 wherein R6 is an optionally substituted (CH2)j- phenyl group.
26. A compound according to any of chemical structures A-N:
Figure imgf000059_0001
H
Figure imgf000059_0002
K
Figure imgf000059_0003
M N wherein RW1, R2™, RYC2 and RZC2 are as described above for compound (II);
Ri, R2, Z1, Z2, Z3, Z4 and Z5 are each independently H, hydroxyl, optionally substituted Ci-Cg alkyl, alkene or alkyne group, optionally substituted C1-C8 acyl group, optionally substituted
Ci-Cio alkoxy, optionally substituted C2-Cg ether, optionally substituted or C2-Cg ester group, an optionally substituted C5-Cn (CH2)j-carbocyclic group wherein said carbocyclic group forms an optionally substituted 5, 6 or 7-membered ring (preferably, a (CH2)j-phenyl group, where the phenyl group is optionally substituted), or an optionally substituted (CH2)m- heterocyclic group (preferably, an optionally substituted heteroaryl) group, alkoxy, halogen, carboxylic acid, cyano, ether, ester, acyl, nitro, amine (including mono- or di- alkyl substituted amines), or (CH2)j-OH;
R3 is H, an optionally substituted Cj-C6 alkyl group, an optionally substituted O-(Ci-C6)alkyl, an optionally substituted aryl group or heterocyclic group; each j is independently 0, 1, 2, 3, 4 or 5; and each m is independently 0, 1, 2, 3, 4, or 5; or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
27. The compound according to claim 26 wherein Ri and R2 are each independently H, CH3, CH2CH3, NH2, NHCH3, N(CH3)2, OH, OCH3, SH, SCH3, F, Cl, Br or I.
28. The compound according to claim 26 or 27 Ri, R2, Zi, Z2, Z3, Z4, Z5 are independently H, hydroxyl, halo, CH3, or OCH3.
29. A compound according to the chemical structure:
Figure imgf000061_0001
Figure imgf000061_0002
Figure imgf000061_0003
30. A compound according to the chemical structure B:
Figure imgf000061_0004
Where R1 and R2 are each independently selected from H, OH, CN, NO2, halogen, Cj-C4 alkyl which is optionally substituted with from one to three hydroxyl groups or from one to three halogen groups, or a -(CH2)JOR3 ,
-(CH2)jC(O)Ra or -(CH2)jOC(O)Ra group, where Ra is H, a CpC3 alkyl group which is optionally substituted with from one to three hydroxyl groups or from one to three halogen groups; and each j is independently 0, 1, 2, or 3;
Zi, Z2, Z3, Z4 and Z5 are each independently H, a Ci-C3 alkyl group which is optionally substituted with from one to three one hydroxyl groups or from one to three halogen groups, or a-(CH2)j0Ra , -<CH2)jC(O)Ra or -(CH2)j0C(0)Ra group, where Ra is H, a Ci-C3 alkyl group which is optionally substituted with from one to three hydroxyl groups or from one to three halogen groups; and each j is independently 0, 1, 2, or 3, or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
31. The compound according to claim 30 wherein Z4 and Z5 are both H.
32. The compound according to claim 30 or 31 wherein Ri is H, CH3, OCH3, F or OH; R2 is H, CH3 or OH; Zi is H or OCH3; Z2 is H, OH or OCH3; and Z3 is H or OCH3 .
33. A compound according to any of claims 30-32 wherein Ri is CH3, R2 is H, Z1 is OCH3, Z2 is H, Z3 is H, Z4is H and Z5 is H.
34. A compound according to any of claims 30-32 wherein Ri is CH3, R2 is H, Zi is H, Z2 is H, Z3 is H, Z4 is H and Z5 is H.
35. A compound according to any of claims 30-32 wherein Ri is H, R2 is OH, Z1 is H, Z2 is H, Z3 is OCH3, Z4 is H and Z5 is H.
36. A compound according to any of claims 30-32 wherein Ri is F, R2 is H, Zi is H, Z2 is H, Z3 is H, Z4 is H and Z5 is H.
37. A compound according to any of claims 30-32 wherein Ri is CH3, R2 is H, Zi is H, Z2 is OH or OCH3, Z3 is H, Z4 is H and Z5 is H.
38. The compound according to claim 37 wherein Z2 is OH.
39. The compound according to claim 37 wherein Z2 is OCH3.
40. A compound according to any of claims 30-32 wherein Ri is OH, R2 is H, Zi is OCH3, Z2 is OCH3, Z3 is H, Z4 is H and Z5 is H.
41. A compound according to the chemical structure:
Figure imgf000063_0001
Where Ri and R2 are each independently selected from H, OH, CN, NO2, halogen, a Ci -C4 alkyl which is optionally substituted with from one to three hydroxyl groups or at least one to three halogen groups, or a -(CH2)jORa , -(CH2)jC(O)Ra or -(CH2)jOC(O)Ra group, where Ra is H, a C1-C3 alkyl group which is optionally substituted with from one to three hydroxyl groups or from one to three halogen groups and each j is independently 0, 1, 2 or 3;
Zi, Z2, Z3, Z4 and Z5 are each independently H, a C1-C3 alkyl group which is optionally substituted with from one to three hydroxyl groups or from one to three halogen groups, or a -(CH2)jORa , -(CH2)jC(O)Ra or -(CH2)jOC(O)Ra group, where Ra is H, a C-C3 alkyl group which is optionally substituted with from one to three hydroxyl groups or from one to three halogen groups; and each j is independently 0, 1, 2, or 3, or a pharmaceutically acceptable salt, enantiomer, solvate or polymorph thereof.
42. The compound according to claim 41 wherein Ri is H, F, Br or CN; R2 is H, F, Cl, CF3, NO2 or CN; Zi is H or OCH3; Z2 is H, OH, CH2OH, CH2OAc, OCH3; Z3 is H, Cl, OCH3; Z4 is H; and Z5 is H.
43. The compound according to claim 41 or 42 wherein Ri is H, R2 is F, Zi is H, Z2 is H, Z3 is Cl, Z4 is H and Z5 is H.
44. The compound according to claim 41 or 42 wherein Ri is F, R2 is H, Zi is H, Z2 is H, Z3 is Cl, Z4 is H and Z5 is H.
45. The compound according to claim 41 or 42 wherein R] is F, R2 is H, Zi is H, Z2 is CH2OAc, Z3 is H, Z4 is H and Z5 is H.
46. The compound according to claim 41 or 42 wherein Rj is CN, R2 is H, Zi is H, Z2 is H, Z3 is Cl, Z4 is H and Z5 is H.
47. A pharmaceutical composition in dosage form comprising an effective amount of at least one compound according to any of claims 1-46 in combination with a pharmaceutically acceptable carrier, additive or excipient.
48. The composition according to claim 47 further comprising an effective amount of an additional anticancer agent or antiviral agent.
49. The composition according to claim 47 or 48 in oral unit dosage form.
50. The composition according to claim 47 or 48 in parenteral unit dosage form.
51. The composition according to claim 47 or 48 in topical unit dosage form.
52. A method of treatment comprising administering to a subject suffering from a disease associated with high MIF expression a therapeutically effective amount of a compound of any one of claims 1-46.
53. The method of claims 52, wherein the disease associated with high MIF expression is an autoimmune disease, cancer, an infection, anemia of chronic disease, malaria, asthma,or autism spectrum disorder.
54. The method of claims 53, wherein the infection associated with high MIF expression is caused by a flavivirus, such as West Nile, Dengue, Japanese encephalitis, St Louis encephalitis, or equine encepahalitis viruses.
55. The method of claim 53 wherein said cancer is stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/CNS, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, leukemia, melanoma, non-melanoma skin cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, glioma, teratoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, kidney cancer or other lymphoma.
56. The method of claim 53 or 55 wherein said cancer is cancer of the ovaries.
57. The method of claim 53 or 55 wherein said compound is administered in combination with at least one additional anticancer agent.
57. A method of treatment comprising administering to a subject suffering from a disease associated with low MIF expression a therapeutically effective amount of a compound of any of claims 1-46.
58. The method of claim 57, wherein the disease associated with low MIF expression is an acute infection, a bacterial infection, a viral infection, a fungal infection, sepsis, an infection that leads to a respiratory disease, a respiratory disease resulting from an infection, infections and diseases caused by gram positive and gram negative bacteria, or mycobacteria.
59. The method of claim 57, wherein the disease associated with low MIF expression is an infection caused by Mycobacterium tuberculosis, Pneumocystis, Candida, Histoplasma, varicella, or corona virus, meningitis, influenza, a retroviral infection, or pneumonia caused by a bacterial, viral or fungal infection.
60. The method of claim 57, wherein the disease associated with low MIF expression is Community Acquired Pneumonia (CAP), HFV infection, or an infection caused by a virus or other pathogen that use the CCR5 receptor for infection.
61. The method of claim 57, wherein the disease associated with low MIF expression is HIV-I, HCV, Epstein-Barr Virus, and Yersinia pestis.
62. A method of treatment comprising administering to a subject who is at risk of developing a disease associated with high or low levels of MIF expression a preventing effective amount of a compound of any of claims 1-46.
63. A method of modulating MIF in a subject comprising administering to said subject an effective amount of a compound according to any of claims 1-46.
64. The method according to claim 63 wherein the action of MIF at the CD44 or CD74 receptors of said subject is reduced or inhibited.
65. The method according to claim 63 wherein the action of MIF at the CD44 or CD74 receptor of said subject is increased or enhanced.
66. Use of a compound according to any of claims 1 -46 in the manufacture of a medicament for the treatment of a disease associated with high MIF expression.
67. Use according to claim 66 wherein said disease is an autoimmune disease, cancer, anemia of chronic disease, malaria, or asthma.
68. Use according to claim 67 wherein wherein said cancer is stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/CNS, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, leukemia, melanoma, non-melanoma skin cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, glioma, teratoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, kidney cancer or other lymphoma.
69. Use according to claim 678 or 68 wherein said disease is cancer of the ovaries.
70. Use of a compound according to any of claims 1 -46 in the manufacture of a medicament for the treatment of a disease associated with low MIF expression.
71. Use according to claim claim 70 wherein said disease associated with low MIF expression is an acute infection, a bacterial infection, a viral infection, a fungal infection, sepsis, an infection that leads to a respiratory disease, a respiratory disease resulting from an infection, infections and diseases caused by gram positive and gram negative bacteria, or mycobacteria.
72. Use according to claim 70 wherein the disease associated with low MIF expression is an infection caused by Mycobacterium tuberculosis, Pneumocystis, Candida, Histoplasma, varicella, or corona virus, meningitis, influenza, a retroviral infection, or pneumonia caused by a bacterial, viral or fungal infection.
73. Use according to claim 70 wherein the disease associated with low MIF expression is Community Acquired Pneumonia (C AP), HIV infection, or an infection caused by a virus or other pathogen that use the CCR5 receptor for infection.
74. Use according to claim 70 wherein the disease associated with low MIF expression is HIV-I, HCV, Epstein-Barr Virus, and Yersinia pestis.
75. Use of a compound according to any of claims 1-46 in the manufacture of a medicament for the treatment of a subject who is at risk of developing a disease associated with high or low levels of MIF.
76. Use of a compound according to any of claims 1-46 in the manufacture of a medicament for modulating MIF in a subject.
77. Use according to claim 76 wherein MIF action at the CD44 or CD74 receptors of said subject is reduced or inhibited.
78. The method according to claim 63 wherein the action of MIF at the CD44 or CD74 receptor of said subject is increased or enhanced.
PCT/US2009/004704 2008-08-18 2009-08-18 Mif modulators WO2010021693A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CN200980141108XA CN102186833A (en) 2008-08-18 2009-08-18 MIF modulators
CA2733554A CA2733554A1 (en) 2008-08-18 2009-08-18 Mif modulators
US13/059,762 US20120040974A1 (en) 2008-08-18 2009-08-18 Mif modulators
EA201170349A EA201170349A1 (en) 2008-08-18 2009-08-18 MIF MODULATORS
MX2011001872A MX2011001872A (en) 2008-08-18 2009-08-18 Mif modulators.
AU2009283195A AU2009283195A1 (en) 2008-08-18 2009-08-18 MIF modulators
JP2011523805A JP2012500260A (en) 2008-08-18 2009-08-18 MIF modulator
EP09808499A EP2326631A4 (en) 2008-08-18 2009-08-18 Mif modulators
BRPI0917394A BRPI0917394A2 (en) 2008-08-18 2009-08-18 mif modulators
US12/773,430 US9643922B2 (en) 2008-08-18 2010-05-04 MIF modulators
IL211170A IL211170A0 (en) 2008-08-18 2011-02-10 Mif modulators
US13/100,922 US9540322B2 (en) 2008-08-18 2011-05-04 MIF modulators
US15/656,555 US10202343B2 (en) 2008-08-18 2017-07-21 MIF modulators
US16/229,069 US11584717B2 (en) 2008-08-18 2018-12-21 MIF modulators
US16/999,015 US20200377457A1 (en) 2008-08-18 2020-08-20 Mif modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18932708P 2008-08-18 2008-08-18
US61/189,327 2008-08-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/773,430 Continuation-In-Part US9643922B2 (en) 2008-08-18 2010-05-04 MIF modulators

Publications (2)

Publication Number Publication Date
WO2010021693A2 true WO2010021693A2 (en) 2010-02-25
WO2010021693A3 WO2010021693A3 (en) 2010-07-01

Family

ID=41707595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/004704 WO2010021693A2 (en) 2008-08-18 2009-08-18 Mif modulators

Country Status (14)

Country Link
US (1) US20120040974A1 (en)
EP (1) EP2326631A4 (en)
JP (1) JP2012500260A (en)
KR (1) KR20110042374A (en)
CN (1) CN102186833A (en)
AU (1) AU2009283195A1 (en)
BR (1) BRPI0917394A2 (en)
CA (1) CA2733554A1 (en)
CL (1) CL2011000352A1 (en)
EA (1) EA201170349A1 (en)
IL (1) IL211170A0 (en)
MX (1) MX2011001872A (en)
PE (1) PE20110368A1 (en)
WO (1) WO2010021693A2 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116355A2 (en) * 2010-03-19 2011-09-22 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
WO2011140202A2 (en) * 2010-05-04 2011-11-10 Yale University Mif modulators
US8436012B2 (en) 2008-08-05 2013-05-07 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
US8563575B2 (en) 2010-06-24 2013-10-22 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8680120B2 (en) 2009-07-27 2014-03-25 Kissei Pharmaceutical Co., Ltd. Indole derivative or pharmaceutically acceptable salt thereof
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EP2929882A1 (en) 2014-04-10 2015-10-14 Mifcare MIF inhibitors
EP2944310A1 (en) 2014-05-16 2015-11-18 Mifcare MIF inhibitors for the acute or chronic treatment of pulmonary hypertension
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
US9549988B2 (en) 2013-06-09 2017-01-24 RJS Biologics Pharmaceutical compounds targeted by MIF affinity-tethered moieties
US9617212B2 (en) 2013-12-17 2017-04-11 Controlled Chemicals, Inc. Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors
US9926312B2 (en) 2013-10-01 2018-03-27 Eisai R&D Management Co., Ltd. 4-azaindole derivatives
US10010556B2 (en) 2013-06-21 2018-07-03 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10166215B2 (en) 2013-06-21 2019-01-01 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10335399B2 (en) 2016-09-27 2019-07-02 Merck Sharp & Dohme Corp. Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use
US10500209B2 (en) 2013-07-31 2019-12-10 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3791873A1 (en) * 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
US11220492B2 (en) 2017-05-17 2022-01-11 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
WO2022087719A1 (en) * 2020-10-28 2022-05-05 University Health Network Methods of treating spondyloarthritis or symptoms thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044622A1 (en) * 2005-10-07 2007-04-19 Yale University Use of mif and mif pathway agonists
CN103172579B (en) * 2011-12-20 2017-02-22 天津市国际生物医药联合研究院 Triazole phenyl amines compound preparation and application
CN103172578B (en) * 2011-12-20 2016-09-14 天津市国际生物医药联合研究院 4-ring end replaces preparation and the purposes of 2-1,2,3-triazole amino benzenes compounds
US10189830B2 (en) * 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9382245B2 (en) 2013-10-11 2016-07-05 Yale University Compounds and methods for treating HIV infections
WO2016050831A1 (en) * 2014-10-01 2016-04-07 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indoles as dengue viral replication inhibitors
JOP20150335B1 (en) * 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc indole derivatives as dengue viral replication inhibitors
JOP20160086B1 (en) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JOP20160198B1 (en) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JO3633B1 (en) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
CN107188864B (en) * 2017-07-28 2019-06-04 安徽师范大学 A kind of N- benzyl benzoxazoles ketone compound and its synthetic method
CN114028399A (en) * 2021-12-18 2022-02-11 郑琳 Application of MIF inhibitor 4-IPP in preparation of medicine for treating brain glioma
CN115814069B (en) * 2022-10-31 2023-07-21 四川大学华西医院 Application of MIF gene knockout tumor cells in preparation of tumor vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
WO2006045505A1 (en) 2004-10-21 2006-05-04 Novartis Ag Mif-inhibitors
WO2007070961A1 (en) 2005-12-21 2007-06-28 Cortical Pty Ltd Mif inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU517587A1 (en) * 1971-08-23 1976-06-15 Медицинска Академие (Инопредприятие) Method for preparing 2-oxphenylurea derivatives
FR2244506B1 (en) * 1973-06-26 1977-02-25 Inst Nat Sante Rech Med
DD111637A1 (en) * 1974-05-13 1975-03-05
DE2550959C3 (en) * 1975-11-13 1980-12-04 Hoechst Ag, 6000 Frankfurt Tetrazolyl-imidazoles and tetrazolyl-benzimidazoles, processes for their preparation and pharmaceuticals containing them
EP0200345A3 (en) * 1985-03-30 1988-03-02 Beecham Group Plc Anti-allergic or anti-inflammatory substituted (hetero)-aralkylamino-ortho-phenols
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
JPH09124620A (en) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co Substituted biphenylsulfonamide endothelin antagonist
AU715202B2 (en) * 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TNSN97083A1 (en) * 1996-05-15 2005-03-15 Bayer Corp INHIBITION OF METALLOPROTEASE MATRICES BY SUBSTITUTION OF OXOBUTYRIC BIARYL ACID
JP3783810B2 (en) * 1997-01-14 2006-06-07 第一製薬株式会社 Novel benzofuranone derivative and method for producing the same
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
ES2249444T3 (en) * 2000-06-05 2006-04-01 Austria Wirtschaftsservice Gesellschaft Mit Beschrankter Haftung HETEROCICLIC HYDRAZONS AS ACTIVE PRINCIPLES AGAINST CANCER.
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
AU8645401A (en) * 2000-08-14 2002-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
US6774134B2 (en) * 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
YU52403A (en) * 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
AR035230A1 (en) * 2001-03-19 2004-05-05 Astrazeneca Ab BENCIMIDAZOL COMPOUNDS, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION, AND USES OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES
US6515176B1 (en) * 2001-12-03 2003-02-04 Eastman Kodak Company 6-Acylamino-5-substituted-benzoxazol-2-one compounds and method for using them
AR038536A1 (en) * 2002-02-25 2005-01-19 Upjohn Co N-ARIL-2-OXAZOLIDINONA-5- CARBOXAMIDS AND ITS DERIVATIVES
WO2003104203A1 (en) * 2002-06-07 2003-12-18 Cortical Pty Ltd Therapeutic molecules and methods-1
AR041198A1 (en) * 2002-10-11 2005-05-04 Otsuka Pharma Co Ltd COMPOUND 2,3-DIHIDRO-6-NITROIMIDAZO [2,1-B] OXAXOL, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
FR2845998A1 (en) * 2002-10-18 2004-04-23 Servier Lab New N-phenyl-benzoxazole or -benzthiazole derivatives, useful for treating e.g. diabetes and cancers, are modulators of the peroxisome-activated receptors
FR2860235A1 (en) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd USE OF A COMPOUND OF FORMULA (I) INHIBITOR OF AROMATASE FOR THERAPEUTIC PURPOSES AND COMPOUNDS OF FORMULA (I) AS SUCH
BRPI0511834A (en) * 2004-07-14 2008-01-08 Ptc Therapeutics Inc methods for treating hepatitis c
RU2007118523A (en) * 2004-10-19 2008-11-27 Новартис Вэксинс Энд Диагностикс Инк. (Us) DERIVATIVES OF INDOL AND BENZIMIDAZOLE
KR20070113252A (en) * 2005-02-25 2007-11-28 쿠도스 파마슈티칼스 리미티드 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
US7576099B2 (en) * 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
SG159561A1 (en) * 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
CA2610354C (en) * 2005-05-31 2011-03-29 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
US7514566B2 (en) * 2006-01-18 2009-04-07 Amgen, Inc. Thiazole compounds and methods of use
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007103550A2 (en) * 2006-03-08 2007-09-13 Achillion Pharmaceuticals, Inc. Substituted aminothiazole derivatives with anti-hcv activity
WO2008013622A2 (en) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
DE102007026341A1 (en) * 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
TWI428091B (en) * 2007-10-23 2014-03-01 Du Pont Fungicidal mixtures
EP2260032A2 (en) * 2008-01-25 2010-12-15 E. I. du Pont de Nemours and Company Fungicidal hetercyclic compounds
JP2011513242A (en) * 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． Prostaglandin D2 receptor antagonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
WO2006045505A1 (en) 2004-10-21 2006-05-04 Novartis Ag Mif-inhibitors
WO2007070961A1 (en) 2005-12-21 2007-06-28 Cortical Pty Ltd Mif inhibitors

Non-Patent Citations (44)

* Cited by examiner, † Cited by third party
Title
BARRECA, M.-L ET AL.: "describe computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 reverse transcriptase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, 2005, pages 3433 - 3437
BERNHAGEN ET AL., BIOCHEMISTRY, vol. 33, 1994, pages 14144 - 14155
BERNHAGEN ET AL., NATURE, vol. 365, 1993, pages 756 - 759
CHENG, K. F; AL-ABED, Y: "Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity", BIOORG. MED. CHEM. LETT, vol. 16, 2006, pages 3376 - 3379, XP025107374, DOI: doi:10.1016/j.bmcl.2006.04.038
DIOS ET AL., J. MED. CHEM., vol. 45, 2002, pages 2410 - 2416
JORGENSEN W. L., ACCOUNTS OF CHEMICAL RESEARCH, vol. 42, no. 6, June 2009 (2009-06-01), pages 724 - 733
JORGENSEN, W. L: "The Many Roles of Computation in Drug Discovery", SCIENCE, vol. 303, 2004, pages 1813 - 1818, XP055058901, DOI: doi:10.1126/science.1096361
KIM KH; XIE Y; TYTLER EM; WOESSNER R; MOR G; ALVERO AB: "KSP inhibitor ARRY-520 is used as a substitute for Paclitaxel in Type I ovarian cancer cells", J TRANSL MED, vol. 7, 2009, pages 63, XP021059150, DOI: doi:10.1186/1479-5876-7-63
LENG L.; METZ C; FANG Y; XU J; DONNELLY S; BAUGH J; DELONERY T; CHEN Y; MITCHELL RA; BUCALA R: "MIF Signal Transduction Initiated by Binding to CD74", J EXP MED, vol. 197, 2003, pages 1467 - 1476, XP009104104, DOI: doi:10.1084/jem.20030286
LENG, L. ET AL.: "MIF signal transduction initiated by binding to CD74", J. EXP. MED., vol. 197, 2003, pages 1467 - 1476, XP009104104, DOI: doi:10.1084/jem.20030286
LENG, L.; METZ, C.; FANG, Y.; XU, J.; DONNELLY, S.; BAUGH, J; DELONERY, T.; CHEN, Y.; MITCHELL, R. A; BUCALA, R: "MIF signal transduction initiated by binding to CD74", J. EXP. MED., vol. 197, 2003, pages 1467 - 1476, XP009104104, DOI: doi:10.1084/jem.20030286
LOLIS ET AL.: "Macrophage migration inhibitory factor", EXPERT OPIN. THERAP. TARGETS, vol. 7, 2003, pages 153 - 164
LOLIS, E; BUCALA, R: "Crystal structure of macrophage migration inhibitory factor (MIF), a glucocorticoid-induced regulator of cytokine production, reveals a unique architecture", PROC. ASSOC. AMER. PHYSICIANS, vol. 108, 1996, pages 415 - 9
LOLIS, E; BUCALA, R: "Macrophage migration inhibitory factor", EXPERT OPIN. THERAP. TARGETS, vol. 7, 2003, pages 153 - 164
LUBETSKY ET AL., JBIOL CHEM, vol. 277, 2002, pages 24976 - 24982
LUBETSKY, J ET AL.: "Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity", BIOCHEMISTRY, vol. 3, no. 8, 1999, pages 7346 - 54
LUBETSKY, J. B ET AL.: "The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents", J. BIOL. CHEM., vol. 277, 2002, pages 24976 - 24982, XP002420977, DOI: doi:10.1074/jbc.M203220200
LUBETSKY, J. B.; DIOS, A.; HAN, J.; ALJABARI, B.; RUZSICSKA, B.; MITCHELL, R.; LOLIS, E; AL ABED, Y: "The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents", J. BIOL. CHEM., vol. 277, 2002, pages 24976 - 24982, XP002420977, DOI: doi:10.1074/jbc.M203220200
LUBETSKY, J. B.; SWOPE, M.; DEALWIS, C.; BLAKE, P; LOLIS, E: "Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity", BIOCHEMISTRY, vol. 38, 1999, pages 7346 - 54
LUBETSKY, J. B: "The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents", J. BIOL. CHEM., vol. 277, 2002, pages 24976 - 24982, XP002420977, DOI: doi:10.1074/jbc.M203220200
MORAND ET AL.: "MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis", NATURE REV. DRUG DISC, vol. 5, 2006, pages 399 - 411
MORAND, E. F.; LEECH, M; BERNHAGEN, J: "MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis", NATURE REV. DRUG DISC, vol. 5, 2006, pages 399 - 411
NAOKI, I.; TAKESHI, S.; ETSUKO, M.; YASUO, K, J. ORG. CHEM, vol. 67, 2002, pages 7424 - 7428
ORITA ET AL.: "Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors", CURR. PHARM. RES., vol. 8, 2002, pages 1297 - 1317, XP008166735, DOI: doi:10.2174/1381612023394674
ORITA, M. ET AL.: "Coumarin and Chromen-4-one Analogues as Tautomerase Inhibitors of Macrophage Migration Inhibitory Factor: Discovery and X-ray Crystallography", J. MED. CHEM., vol. 44, 2001, pages 540 - 547, XP002602934, DOI: doi:10.1021/JM000386O
ORITA, M.; YAMAMOTO, S.; KATAYAMA, N.; AOKI, M.; KAZUHISA, T.; YAMAGIWA, Y.; SEKI, N.; SUZUKI, H.; KURIHARA, H.; SAKASHITA, H.: "Coumarin and Chromen-4-one Analogues as Tautomerase Inhibitors of Macrophage Migration Inhibitory Factor: Discovery and X-ray Crystallography", J. MED. CHEM., vol. 44, 2001, pages 540 - 547
ORITA, M.; YAMAMOTO, S.; KATAYAMA, N.; FUJITA, S: "Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors", CURR. PHARM. RES, vol. 8, 2002, pages 1297 - 1317, XP008166735, DOI: doi:10.2174/1381612023394674
PIRRUNG, M. C.; CHEN, J.; ROWLEY, E. G.; MCPHAIL, A.T: "Mechanistic and stereochemical study of phenylpyruvate tautomerase", J. AM. CHEM. SOC., vol. 115, 1993, pages 7103 - 10, XP002064658, DOI: doi:10.1021/ja00069a006
PROC. NAT. ACAD. SCI. USA, vol. 99, 2002, pages 144 - 9
ROSENGREN, E. ET AL.: "The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction", MOLEC. MED, vol. 2, 1996, pages 143 - 149, XP000886223, DOI: doi:10.1016/1357-4310(96)88782-X
ROSENGREN, E. ET AL.: "The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase", FEBS LETT, vol. 417, 1997, pages 85 - 8, XP004261397, DOI: doi:10.1016/S0014-5793(97)01261-1
ROSENGREN, E.; AMAN, P.; THELIN, S.; HANSSON, C.; AHLFORS, S.; BJORK, P.; JACOBSSON, L; RORSMAN, H: "The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase", FEBS LETT, vol. 417, 1997, pages 85 - 8, XP004261397, DOI: doi:10.1016/S0014-5793(97)01261-1
ROSENGREN, E.; BUCALA, R.; AMAN, P.; JACOBSSON, L.; ODH, G.; METZ, C. N; RORSMAN, H: "The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction", MOLEC. MED, vol. 2, 1996, pages 143 - 149, XP000886223, DOI: doi:10.1016/1357-4310(96)88782-X
See also references of EP2326631A4
SENTER ET AL., PROC NATL ACAD SCI USA, vol. 99, 2002, pages 144 - 149
SENTER, P. D. ET AL.: "Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites", PROC. NAT. ACAD. SCI. USA, vol. 99, 2002, pages 144 - 9, XP008061096, DOI: doi:10.1073/pnas.011569399
SENTER, P. D.; AL-ABED, Y.; METZ, C. N.; BENIGNI, F.; MITCHELL, R. A.; CHESNEY, J.; HAN, J.; GARTNER, C. G.; NELSON, S. D.; TODARO: "Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites", PROC. NAT. ACAD. SCI. USA, vol. 99, 2002, pages 144 - 9, XP008061096, DOI: doi:10.1073/pnas.011569399
SENTER: "However, some potent tautomerase inhibitors do not inhibit the biological activity of MIF", SENTER, 2002
STAMPS, S. L.: "Mechanism of the Phenylpyruvate Tautomerase Activity of Macrophage Migration Inhibitory Factor: Properties of the PIG, P1A, Y95F, and N97A Mutants", BIOCHEMISTRY, vol. 39, 2000, pages 9671 - 9678, XP003013135, DOI: doi:10.1021/bi000373c
STAMPS, S. L.; TAYLOR, A. B.; WANG, S. C.; HACKERT, M. L; WHITMAN, C. P: "Mechanism of the Phenylpyruvate Tautomerase Activity of Macrophage Migration Inhibitory Factor: Properties of the PIG, P1A, Y95F, and N97A Mutants", BIOCHEMISTRY, vol. 39, 2000, pages 9671 - 9678, XP003013135, DOI: doi:10.1021/bi000373c
SUN, H ET AL.: "Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor", PROC. NAT. ACAD. SCI. USA, vol. 93, 1996, pages 5191 - 5196
SUN, H. W.; BERNHAGEN, J.; BUCALA, R; LOLIS, E: "Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor", PROC. NAT. ACAD. SCI. USA, vol. 93, 1996, pages 5191 - 5196
WEISS; GOODNOUGHT: "Anemia of Chronic Disease", N. ENGL. J. MED, vol. 352, no. 10, 2005, pages 1011 - 23
ZHANG, X.; BUCALA, R: "Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs", BIOORG. MED. CHEM. LETT, vol. 9, 1999, pages 3193 - 3198, XP004185505, DOI: doi:10.1016/S0960-894X(99)00561-2

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8436012B2 (en) 2008-08-05 2013-05-07 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
US8785438B2 (en) 2008-08-05 2014-07-22 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US11584717B2 (en) 2008-08-18 2023-02-21 Yale University MIF modulators
US10202343B2 (en) 2008-08-18 2019-02-12 Yale University MIF modulators
US8680120B2 (en) 2009-07-27 2014-03-25 Kissei Pharmaceutical Co., Ltd. Indole derivative or pharmaceutically acceptable salt thereof
WO2011116355A2 (en) * 2010-03-19 2011-09-22 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
WO2011116355A3 (en) * 2010-03-19 2012-03-01 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
WO2011140202A3 (en) * 2010-05-04 2012-11-01 Yale University Mif modulators
WO2011140202A2 (en) * 2010-05-04 2011-11-10 Yale University Mif modulators
US8846713B2 (en) 2010-06-24 2014-09-30 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors
US8563575B2 (en) 2010-06-24 2013-10-22 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8940758B2 (en) 2010-06-24 2015-01-27 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US9226921B2 (en) 2010-06-24 2016-01-05 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US9549988B2 (en) 2013-06-09 2017-01-24 RJS Biologics Pharmaceutical compounds targeted by MIF affinity-tethered moieties
US10772892B2 (en) 2013-06-21 2020-09-15 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US11446306B2 (en) 2013-06-21 2022-09-20 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US11026926B2 (en) 2013-06-21 2021-06-08 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US10010556B2 (en) 2013-06-21 2018-07-03 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10363257B2 (en) 2013-06-21 2019-07-30 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
US10166215B2 (en) 2013-06-21 2019-01-01 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US10226451B2 (en) 2013-06-21 2019-03-12 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US10500209B2 (en) 2013-07-31 2019-12-10 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
US10072005B2 (en) 2013-10-01 2018-09-11 Eisai R&D Management Co., Ltd. 4-azaindole derivatives
US9926312B2 (en) 2013-10-01 2018-03-27 Eisai R&D Management Co., Ltd. 4-azaindole derivatives
US9617212B2 (en) 2013-12-17 2017-04-11 Controlled Chemicals, Inc. Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
EP2929882A1 (en) 2014-04-10 2015-10-14 Mifcare MIF inhibitors
WO2015155358A1 (en) * 2014-04-10 2015-10-15 Mifcare Mif inhibitors
US10160732B2 (en) 2014-04-10 2018-12-25 Mifcare MIF inhibitors
WO2015173433A1 (en) 2014-05-16 2015-11-19 Mifcare Mif inhibitors for the acute or chronic treatment of pulmonary hypertension
US10071080B2 (en) 2014-05-16 2018-09-11 Mifcare MIF inhibitors for the acute or chronic treatment of pulmonary hypertension
EP2944310A1 (en) 2014-05-16 2015-11-18 Mifcare MIF inhibitors for the acute or chronic treatment of pulmonary hypertension
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US10335399B2 (en) 2016-09-27 2019-07-02 Merck Sharp & Dohme Corp. Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use
US10806724B2 (en) 2016-09-27 2020-10-20 Merck Sharp & Dohme Corp. Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use
US11220492B2 (en) 2017-05-17 2022-01-11 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
EP3791873A1 (en) * 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
WO2022087719A1 (en) * 2020-10-28 2022-05-05 University Health Network Methods of treating spondyloarthritis or symptoms thereof

Also Published As

Publication number Publication date
EP2326631A2 (en) 2011-06-01
PE20110368A1 (en) 2011-06-13
KR20110042374A (en) 2011-04-26
CN102186833A (en) 2011-09-14
IL211170A0 (en) 2011-04-28
CL2011000352A1 (en) 2011-09-23
BRPI0917394A2 (en) 2019-09-24
US20120040974A1 (en) 2012-02-16
WO2010021693A3 (en) 2010-07-01
AU2009283195A1 (en) 2010-02-25
CA2733554A1 (en) 2010-02-25
MX2011001872A (en) 2011-05-23
EP2326631A4 (en) 2012-03-21
JP2012500260A (en) 2012-01-05
EA201170349A1 (en) 2011-08-30

Similar Documents

Publication Publication Date Title
US11584717B2 (en) MIF modulators
WO2010021693A2 (en) Mif modulators
US9643922B2 (en) MIF modulators
JP6516705B2 (en) Sulfamoyl benzamide derivatives as antiviral agents against HBV infection
EP3349761B1 (en) Hepatitis b core protein modulators
TWI519515B (en) Hepatitis b antiviral agents
WO2016131381A1 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
US10428041B2 (en) Pyridyl reverse sulfonamides for HBV treatment
FI120537B (en) Trisubstituted phenyl derivatives
CN113292565B (en) Nucleoside compound and preparation method and application thereof
US7579353B2 (en) Pyridinone derivatives against malaria
EA034868B1 (en) Pyridazinone compounds and uses thereof
EP3068758B1 (en) Ebna1 inhibitors and their method of use
WO2014089296A2 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
WO2021193756A1 (en) Novel benzimidazole derivative
WO2011073114A1 (en) Heterocyclic antiviral compounds
WO2021191872A1 (en) Heteroaryl-substituted macrocyclic flu endonuclease inhibitors
US20110306621A1 (en) Acylguanidine derivatives
Kuramoto et al. Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer
US8486959B2 (en) Dibenzo[f,h]isoquinoline derivatives
EP2867213A1 (en) Dihydropyrimidin-2(1h)-ones and dihydropyrimidin-2(1h)-thiones as inhibitors of sodium iodide symporter
CN114315827A (en) Polycyclic pyridopyridazine amide oxime-containing carbocyclic derivatives and uses thereof
KR20080071343A (en) Compound having antivirus activity against influenza virus and process for preparing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980141108.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09808499

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2733554

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 211170

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12011500328

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 000163-2011

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2011523805

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011000352

Country of ref document: CL

Ref document number: 2009283195

Country of ref document: AU

Ref document number: MX/A/2011/001872

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011020269

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 591552

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2009283195

Country of ref document: AU

Date of ref document: 20090818

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1110/KOLNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117006166

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201170349

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2009808499

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: a201103153

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 13059762

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0917394

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110218